Tactile Systems Technology (TCMD) 10-Q 8 Nov 21 2021 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2021	Nov. 04, 2021
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2021
Document Transition Report	false
Entity File Number	001-37799
Entity Registrant Name	Tactile Systems Technology, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	41-1801204
Entity Address, Address Line One	3701 Wayzata Blvd, Suite 300
Entity Address, City or Town	Minneapolis
Entity Address, State or Province	MN
Entity Address, Postal Zip Code	55416
City Area Code	612
Local Phone Number	355-5100
Title of 12(b) Security	Common Stock
Trading Symbol	TCMD
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		19,823,022
Entity Central Index Key	0001027838
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Amendment Flag	false

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets
Cash and cash equivalents	$ 22,401	$ 47,855
Accounts receivable	44,257	43,849
Net investment in leases	12,385	10,708
Inventories	23,830	18,563
Prepaid expenses and other current assets	3,701	2,638
Total current assets	106,574	123,613
Non-current assets
Property and equipment, net	6,458	6,957
Right of use operating lease assets	23,919	20,132
Intangible assets, net	54,970	1,680
Goodwill	31,063
Accounts receivable, non-current	12,422	9,433
Deferred income taxes	11,907	10,198
Other non-current assets	2,082	2,074
Total non-current assets	142,821	50,474
Total assets	249,395	174,087
Current liabilities
Accounts payable	6,192	4,197
Note payable	2,210
Accrued payroll and related taxes	10,322	11,588
Accrued expenses	5,350	4,423
Income taxes payable	1,129	2,658
Operating lease liabilities	2,412	2,006
Other current liabilities	3,694	1,842
Total current liabilities	31,309	26,714
Non-current liabilities
Revolving line of credit, non-current	24,844
Note payable, non-current	27,673
Earn-out, non-current	6,400
Accrued warranty reserve, non-current	3,358	3,235
Income taxes payable, non-current	348
Operating lease liabilities, non-current	23,357	19,388
Total non-current liabilities	85,980	22,623
Total liabilities	117,289	49,337
Commitments and Contingencies (see Note 11)
Stockholders' equity:
Preferred stock, $0.001 par value, 50,000,000 shares authorized; none issued and outstanding as of September 30, 2021 and December 31, 2020
Common stock, $0.001 par value, 300,000,000 shares authorized; 19,797,723 shares issued and outstanding as of September 30, 2021; 19,492,718 shares issued and outstanding as of December 31, 2020	20	19
Additional paid-in capital	116,346	104,675
Retained earnings	15,740	20,056
Total stockholders' equity	132,106	124,750
Total liabilities and stockholders' equity	$ 249,395	$ 174,087

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2021	Dec. 31, 2020
Condensed Consolidated Balance Sheets
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	50,000,000	50,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common shares authorized	300,000,000	300,000,000
Common stock, shares, issued	19,797,723	19,492,718
Common stock, shares, outstanding	19,797,723	19,492,718

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Total revenue	$ 52,497	$ 49,092	$ 146,329	$ 127,887
Total cost of revenue	15,529	14,120	42,926	36,930
Gross profit	36,968	34,972	103,403	90,957
Operating expenses
Sales and marketing	22,231	19,488	61,949	59,856
Research and development	1,409	1,102	3,885	3,891
Reimbursement, general and administrative	14,500	12,539	42,802	37,682
Intangible asset amortization	195	49	294	148
Total operating expenses	38,335	33,178	108,930	101,577
(Loss) income from operations	(1,367)	1,794	(5,527)	(10,620)
Other (expense) income	(120)	(121)	(154)	181
(Loss) income before income taxes	(1,487)	1,673	(5,681)	(10,439)
Income tax expense (benefit)	1,868	(751)	(1,365)	2,294
Net (loss) income	$ (3,355)	$ 2,424	$ (4,316)	$ (12,733)
Net (loss) income per common share
Basic (in dollars per share)	$ (0.17)	$ 0.12	$ (0.22)	$ (0.66)
Diluted (in dollars per share)	$ (0.17)	$ 0.12	$ (0.22)	$ (0.66)
Weighted-average common shares used to compute net (loss) income per common share
Basic (in shares)	19,790,838	19,415,640	19,676,749	19,309,344
Diluted (in shares)	19,790,838	19,747,365	19,676,749	19,309,344
Sales revenue
Total revenue	$ 44,460	$ 42,573	$ 124,215	$ 109,714
Total cost of revenue	13,096	11,558	36,425	30,868
Gross profit	31,364	31,015	87,790	78,846
Rental revenue
Total revenue	8,037	6,519	22,114	18,173
Total cost of revenue	2,433	2,562	6,501	6,062
Gross profit	$ 5,604	$ 3,957	$ 15,613	$ 12,111

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Condensed Consolidated Statements of Comprehensive (Loss) Income
Net (loss) income	$ (3,355)	$ 2,424	$ (4,316)	$ (12,733)
Other comprehensive loss
Unrealized loss on marketable securities		(14)		(21)
Income tax related to items of other comprehensive loss		(15)		(5)
Total other comprehensive loss		(29)		(26)
Comprehensive (loss) income	$ (3,355)	$ 2,395	$ (4,316)	$ (12,759)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock	Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive (Loss) Income	Total
Balances at the beginning at Dec. 31, 2019	$ 19	$ 91,874	$ 20,676	$ 26	$ 112,595
Balances at the beginning (in shares) at Dec. 31, 2019	19,152,715
Increase (Decrease) in Stockholders' Equity
Stock-based compensation		8,288			8,288
Exercise of common stock options and vesting of performance and restricted stock units		762			762
Exercise of common stock options and vesting of performance and restricted stock units (in shares)	259,406
Taxes paid for net share settlement of performance and restricted stock units		(1,592)			(1,592)
Taxes paid for net share settlement of performance and restricted stock units (in shares)	(31,095)
Common shares issued for employee stock purchase plan		1,825			1,825
Common shares issued for employee stock purchase plan (in shares)	43,653
Comprehensive income (loss) for the period			(12,733)	(26)	(12,759)
Balances at the end at Sep. 30, 2020	$ 19	101,157	7,943		109,119
Balances at the end (in shares) at Sep. 30, 2020	19,424,679
Balances at the beginning at Jun. 30, 2020	$ 19	97,818	5,519	29	103,385
Balances at the beginning (in shares) at Jun. 30, 2020	19,411,404
Increase (Decrease) in Stockholders' Equity
Stock-based compensation		3,164			3,164
Exercise of common stock options and vesting of performance and restricted stock units		214			214
Exercise of common stock options and vesting of performance and restricted stock units (in shares)	14,322
Taxes paid for net share settlement of performance and restricted stock units		(39)			(39)
Taxes paid for net share settlement of performance and restricted stock units (in shares)	(1,047)
Comprehensive income (loss) for the period			2,424	$ (29)	2,395
Balances at the end at Sep. 30, 2020	$ 19	101,157	7,943		109,119
Balances at the end (in shares) at Sep. 30, 2020	19,424,679
Balances at the beginning at Dec. 31, 2020	$ 19	104,675	20,056		124,750
Balances at the beginning (in shares) at Dec. 31, 2020	19,492,718
Increase (Decrease) in Stockholders' Equity
Stock-based compensation		7,703			7,703
Exercise of common stock options and vesting of performance and restricted stock units	$ 1	3,583			3,584
Exercise of common stock options and vesting of performance and restricted stock units (in shares)	284,829
Taxes paid for net share settlement of performance and restricted stock units		(1,157)			(1,157)
Taxes paid for net share settlement of performance and restricted stock units (in shares)	(21,918)
Common shares issued for employee stock purchase plan		1,542			1,542
Common shares issued for employee stock purchase plan (in shares)	42,094
Comprehensive income (loss) for the period			(4,316)		(4,316)
Balances at the end at Sep. 30, 2021	$ 20	116,346	15,740		132,106
Balances at the end (in shares) at Sep. 30, 2021	19,797,723
Balances at the beginning at Jun. 30, 2021	$ 20	113,601	19,095		132,716
Balances at the beginning (in shares) at Jun. 30, 2021	19,782,295
Increase (Decrease) in Stockholders' Equity
Stock-based compensation		2,588			2,588
Exercise of common stock options and vesting of performance and restricted stock units		199			199
Exercise of common stock options and vesting of performance and restricted stock units (in shares)	16,366
Taxes paid for net share settlement of performance and restricted stock units		(42)			(42)
Taxes paid for net share settlement of performance and restricted stock units (in shares)	(938)
Comprehensive income (loss) for the period			(3,355)		(3,355)
Balances at the end at Sep. 30, 2021	$ 20	$ 116,346	$ 15,740		$ 132,106
Balances at the end (in shares) at Sep. 30, 2021	19,797,723

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows from operating activities
Net loss	$ (4,316)	$ (12,733)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	2,150	2,102
Net amortization of premiums and discounts on securities available-for-sale		(91)
Deferred income taxes	(1,709)	3,934
Stock-based compensation expense	7,703	8,288
Gain on other investments and maturities of marketable securities		10
Impairment losses		4,025
Loss on disposal of property and equipment	7
Changes in assets and liabilities, net of acquisition:
Accounts receivable	(408)	(2,589)
Net investment in leases	(1,677)	(1,304)
Inventories	(3,641)	(3,538)
Income taxes	(1,181)	773
Prepaid expenses and other assets	(1,133)	(1,553)
Right of use operating lease assets	588	509
Medicare accounts receivable, non-current	(2,989)	(2,916)
Accounts payable	1,995	938
Accrued payroll and related taxes	(1,266)	766
Accrued expenses and other liabilities	2,902	1,134
Net cash used in operating activities	(2,975)	(2,245)
Cash flows from investing activities
Proceeds from maturities of securities available-for-sale		22,500
Payments related to acquisition	(79,829)
Purchases of property and equipment	(1,221)	(1,623)
Intangible assets costs	(187)	(163)
Other investments		(30)
Net cash (used in) provided by investing activities	(81,237)	20,684
Cash flows from financing activities
Proceeds from issuance of note payable	30,000
Proceeds from revolving line of credit	25,000
Payment of deferred debt issuance costs	(211)
Taxes paid for net share settlement of performance and restricted stock units	(1,157)	(1,592)
Proceeds from exercise of common stock options	3,584	762
Proceeds from the issuance of common stock from the employee stock purchase plan	1,542	1,825
Net cash provided by financing activities	58,758	995
Net (decrease) increase in cash and cash equivalents	(25,454)	19,434
Cash and cash equivalents - beginning of period	47,855	22,770
Cash and cash equivalents - end of period	22,401	42,204
Supplemental cash flow disclosure
Cash paid for taxes	$ 1,541	475
Capital expenditures incurred but not yet paid		$ 41

Nature of Business and Operatio

Nature of Business and Operations	9 Months Ended
	Sep. 30, 2021
Nature of Business and Operations
Nature of Business and Operations	Note 1. Nature of Business and Operations Tactile Systems Technology, Inc. (“we,” “us,” and “our”) is the sole manufacturer and distributor of the Flexitouch® and Entre™ systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition. We provide these products through our direct sales force for use in the home and sell or rent them through vascular, wound and lymphedema clinics throughout the United States. On September 8, 2021, we acquired the assets of the AffloVest respiratory therapy business (“AffloVest Acquisition”) from International Biophysics Corporation (“IBC”), a privately-held company which developed and manufactures AffloVest. AffloVest is a portable, wearable vest that treats patients with chronic respiratory conditions. The device is sold through home medical equipment and durable medical equipment providers throughout the United States. We were originally incorporated in Minnesota under the name Tactile Systems Technology, Inc. on January 30, 1995. During 2006, we established a merger corporation and subsequently, on July 21, 2006, merged with and into this merger corporation, resulting in our reincorporation as a Delaware corporation. The resulting corporation assumed the name Tactile Systems Technology, Inc. In September 2013, we began doing business as “Tactile Medical”. On August 2, 2016, we closed the initial public offering of our common stock, which resulted in the sale of 4,120,000 shares of our common stock at a public offering price of $10.00 per share. We received net proceeds from the initial public offering of approximately $35.4 million, after deducting underwriting discounts and approximately $2.9 million of transaction expenses. In connection with the closing of the initial public offering, all of our outstanding redeemable convertible preferred stock automatically converted to common stock on August 2, 2016. Our business is affected by seasonality. In the first quarter of each year, when most patients have started a new insurance year and have not yet met their annual out-of-pocket payment obligations, we experience substantially reduced demand for our products. We typically experience higher revenue in the third and fourth quarters of the year when patients have met their annual insurance deductibles, thereby reducing their out-of-pocket costs for our products, and because patients desire to exhaust their flexible spending accounts at year end. This seasonality applies only to purchases and rentals of our products by patients covered by commercial insurance and is not relevant to Medicare, Medicaid or the Veterans Administration, as those payers either do not have plans that have declining deductibles over the course of the plan year and/or do not have plans that include patient deductibles for purchases or rentals of our products. Further, seasonality trends in 2021 may be significantly different than in prior years as a result of the COVID-19 pandemic and related impacts .

Basis of Presentation

Basis of Presentation	9 Months Ended
	Sep. 30, 2021
Basis of Presentation
Basis of Presentation	Note 2. Basis of Presentation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. The results for the nine months ended September 30, 2021, are not necessarily indicative of results to be expected for the year ending December 31, 2021, or for any other interim period or for any future year. The condensed consolidated interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Tactile Systems Technology, Inc. and its wholly owned subsidiary, Swelling Solutions, Inc. All intercompany balances and transactions have been eliminated in consolidation. Risks and Uncertainties Coronavirus (COVID-19) The United States economy in general and our business specifically have been negatively affected by the COVID-19 pandemic. We have seen adverse impacts as it relates to the decline in the number of patients that healthcare facilities and clinics are able to treat due to enhanced safety protocols, particularly during 2020 and the first quarter of 2021. While we saw some level of recovery in the second quarter of 2021, the third quarter was negatively impacted by the prolonged recovery from COVID-19 and increased Delta variant cases during the period, which resulted in restricted access to clinics and hospitals and disrupted the recovery in patient visits versus the pre-COVID environment. There are no reliable estimates of how long the pandemic will last, whether any recovery will be sustained or will reverse course, the severity of any resurgence of COVID-19 or variant strains of the virus, the effectiveness of vaccines and attitudes towards receiving them, or what ultimate effects the pandemic will have. For that reason, we are unable to reasonably estimate the long-term impact of the pandemic on our business at this time. Since the onset of COVID-19, we have remained proactive to ensure we continue to adapt to the needs of our employees, clinicians and patients . We cannot assure you that these changes to our processes and practices will be successful in mitigating the impact of COVID-19 on our business. We continue to evaluate and, if appropriate, will adopt other measures in the future related to the ongoing safety of our employees, clinicians and patients. In addition, we are closely monitoring mandatory vaccination requirements and related evolving guidance that is or may be applicable to us, including in our capacity as a U.S. government contractor. See See Part II, I tem 1A. “ Risk Factors” in this Form 10-Q for additional information about vaccine mandates and potential risks related thereto. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and to disclose contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Comprehensive (Loss) Income Comprehensive (loss) income reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive (loss) income represents net (loss) income adjusted for unrealized gains and losses on available-for-sale marketable securities and the related taxes.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	Note 3. Summary of Significant Accounting Policies Significant Accounting Policies There were no material changes in our significant accounting policies during the nine months ended September 30, 2021, except as set forth below. See Note 3 – “Summary of Significant Accounting Policies” to the consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2020, for information regarding our significant accounting policies. Business Segments We operate and report in only one operating and reportable segment. Our chief operating decision maker does not use financial information below revenue to allocate resources. Goodwill Goodwill represents the excess of the purchase price paid over the estimated fair value of the net assets acquired and liabilities assumed in the acquisition of a business. Goodwill is not amortized, but is tested for impairment at least annually or on an interim basis if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. We plan to perform our annual assessment of goodwill for impairment as of July 1st of each fiscal year. See Note 7 – “Goodwill and Intangible Assets” for additional information. Revenue Recognition for AffloVest The AffloVest device is sold through home medical equipment and durable medical equipment providers (collectively, "distributors"). Revenue is recognized when control of the promised goods or services is transferred to the distributors, in an amount that reflects the consideration we expect to be entitled to in exchange for transferring those goods or providing services. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. When determining whether the distributor has obtained control of the goods or services, we consider any future performance obligations. Generally, there is no post-shipment obligation on products sold other than warranty obligations in the normal and ordinary course of business. ​ In general, revenue from the sale of the AffloVest product is recognized at shipment, unless circumstances dictate that control has not yet passed to the distributor. ​ Certain of our contracts include volume-based incentives which involve rebates that are negotiated at or prior to the time of sale with the customer and are redeemable only if the customer achieves a specified cumulative level of sales or sales increase. Under these incentive programs, at the time of sale, we determine the most likely amount of the rebate to be paid based on forecasted sales levels. These forecasts are updated at least quarterly for each customer, and the transaction price is reduced for the anticipated cost of the rebate. If the forecasted sales for a customer change, the accrual for rebates is adjusted to reflect the new rebates expected to be earned by the customer. ​ Amounts billed to customers for shipping and handling activities after the customer obtains control are treated as a promised service performance obligation and recorded in revenue in the accompanying Consolidated Statements of Operations. Shipping and handling costs incurred for the delivery of goods to customers are considered a cost to fulfill the contract and are included in cost of revenue sold in the accompanying Consolidated Statements of Operations. ​ For a description of our revenue recognition policies related to our Flexitouch and Entre systems, see Note 3 – “Summary of Significant Accounting Policies” to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020. ​ Accounting Pronouncement Not Yet Adopted In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-04, “Reference Rate Reform (Topic 848) — Facilitation of the Effect of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”), addressing the discontinuation of LIBOR, a widely used reference rate for pricing financial products. The ASU is intended to provide optional expedients and exceptions if certain criteria are met when accounting for contracts, hedging relationships and other transactions that reference LIBOR, or another reference rate expected to be discontinued because of reference rate reform. The application and adoption requirements of ASU 2020-04 are optional until December 31, 2022 and vary based on expedients elected. We have not elected any expedients to date and are currently evaluating any potential future impacts on the condensed consolidated financial statements. Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740) — Simplifying the Accounting for Income Taxes” (“ASU 2019-12”), which is intended to simplify various aspects of the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. We adopted ASU 2019-12 as of January 1, 2021, and it did not have an impact on the condensed consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments — Credit Losses” (“ASU 2016-13”), which introduced a new model for recognizing credit losses on financial instruments based on an estimate of the current expected credit losses. The new current expected credit losses (“CECL”) model generally calls for the immediate recognition of all expected credit losses and applies to financial instruments and other assets, including accounts receivable and other financial assets measured at amortized cost, debt securities and other financial assets. This guidance replaced the previous incurred loss model for measuring expected credit losses and requires expected losses on available-for-sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities. We adopted ASU 2016-13 as of January 1, 2020, and it did not have an impact on the consolidated financial statements at that time. In connection with the AffloVest Acquisition, it was determined CECL did not have a material financial impact on the receivables related to the durable medical equipment channel.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 30, 2021
Acquisitions
Acquisitions	Note 4. Acquisitions On September 8, 2021, we entered into an Asset Purchase Agreement (“AffloVest APA”) to acquire the AffloVest therapy business from International Biophysics Corporation. Under the terms of the AffloVest APA, we agreed to pay IBC a total of up to $100.0 million for the purchase of substantially all of the assets related to its branded high frequency chest wall oscillation vest therapy business, other than specifically identified excluded assets. We acquired AffloVest to further expand our position as a leader in treating patients with underserved chronic conditions in the home. The acquired assets included inventory, tooling, intellectual property, permits and approvals, data and records, and customer and supplier information. At closing, $80.0 million of the purchase price was paid, of which a total of $0.5 million was deposited into an escrow account at closing for purposes of satisfying certain post-closing purchase price adjustments and indemnification claims. Subsequent to closing, $0.2 milion was returned to us as a result of working capital adjustments. The AffloVest acquisition was funded through a combination of cash on hand and proceeds from borrowings. Two earn-out payments of up to $10.0 million each are potentially due to IBC under the AffloVest APA depending on the achievement of specified revenue targets, as follows: ​ ● Initial Earn-Out: Equal to 1.5 times the amount by which the AffloVest business’ U.S. revenues in the period from October 1, 2021 to September 30, 2022 (the “Initial Earn-Out Period”) exceed a specified amount; provided that in no event will the payment exceed $10.0 million; and ● Second Earn-Out: Equal to 1.5 times the amount by which the AffloVest business’ U.S. revenues in the period from October 1, 2022 to September 30, 2023 exceed the revenues recognized during the Initial Earn-Out Period; provided that in no event will the payment exceed $10.0 million. ​ This liability was recorded on the Condensed Consolidated Balance Sheet at September 30, 2021 in the line item Earn-out, non-current, at an acquisition-date fair value of $6.4 million. The fair value of the earn-out, reflecting management’s estimate of the likelihood of achieving these targets, was determined by employing a Monte Carlo Simulation model. This amount will be re-measured at the end of each reporting period until the payment requirement ends, with any adjustments reported in income from operations. ​ ​ On the date of AffloVest Acquisition, we allocated the assets acquired based on an estimate of their fair values. The following table summarizes the purchase price allocation: ​ ​ ​ ​ ​ (In millions) Allocated Fair Value Inventories ​ $ 1.6 Property and equipment (1) ​ ​ — Intangible assets ​ ​ 53.5 Goodwill ​ ​ 31.1 Purchase price ​ $ 86.2 ​ (1) The purchase price included less than $0.1 million of property and equipment. The goodwill reflects expected synergies of combining the acquired products and customer information with our existing operations, and is deductible for tax purposes over 15 years . ​ The following table reflects the allocation of purchase price to the acquired intangible assets and related estimated useful lives: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (In millions) Allocated Fair Value ​ Estimated Useful Life Customer relationships ​ $ 31.0 ​ 13 years Developed technology ​ ​ 13.0 ​ 11 years Tradenames ​ 9.5 ​ Indefinite Total intangible assets ​ $ 53.5 ​ ​ ​ The weighted-average amortization period of the acquired intangible assets was 12.3 years. ​ The fair market valuations associated with the assets acquired fall within Level 3 of the fair value hierarchy, due to the use of significant unobservable inputs to determine fair value. The fair value measurements were calculated using unobservable inputs, primarily using the income approach, specifically the discounted cash flow method. The amount and timing of future cash flows within our analysis was based on our due diligence models, most recent operational budgets, long-range strategic plans and other estimates. ​ Transaction costs, such as legal and other costs, related to the acquisition aggregated approximately $0.8 million. These costs have been expensed as incurred and are included in reimbursement, general and administrative expenses in our Condensed Consolidated Statements of Operations. ​ The Condensed Consolidated Statements of Operations reflect the AffloVest operations beginning September 9, 2021. The following unaudited pro forma information for the three and nine months ended September 30, 2021 and the three and nine months ended September 30, 2020 presents the revenues and net income assuming the acquisition of AffloVest had occurred as of January 1, 2020. This information has been prepared for comparative purposes only and is not indicative of what actual results would have been if the acquisition had taken place at the beginning of fiscal 2020, or of future results. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, (In thousands) 2021 ​ 2020 ​ 2021 ​ 2020 Total revenue ​ $ 56,249 ​ $ 53,068 ​ $ 157,686 ​ $ 139,130 Net income (loss) ​ $ 628 ​ $ (309) ​ $ 1,369 ​ $ 1,770 ​ These pro forma results include certain adjustments, primarly due to increases in amortization expense due to fair value adjustments of intangible assets, increases in interest expense due to additional borrowings incurred to finance the acquisition and amortization of debt issuance costs incurred to finance the transaction, acquisition related costs including transaction costs such as legal, accounting, valuation and other professional services, and related tax effects.

Marketable Securities

Marketable Securities	9 Months Ended
	Sep. 30, 2021
Marketable Securities
Marketable Securities	​ Note 5. Marketable Securities There were no investments in marketable securities at September 30, 2021 and December 31, 2020. There were no net pre-tax unrealized gains for marketable securities at September 30, 2021. There were no sales of marketable securities during the nine months ended September 30, 2021. There were no marketable securities in an unrealized loss position at September 30, 2021 and December 31, 2020.

Inventories

Inventories	9 Months Ended
	Sep. 30, 2021
Inventories
Inventories	Note 6. Inventories Inventories consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) At September 30, 2021 At December 31, 2020 Finished goods ​ $ 9,607 ​ $ 7,129 Component parts and work-in-process ​ 14,223 ​ 11,434 Total inventories ​ $ 23,830 ​ $ 18,563 ​

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2021
Intangible Assets
Goodwill and Intangible Assets	Note 7. Goodwill and Intangible Assets Goodwill In the third quarter of fiscal 2021, we completed the AffloVest Acqusition. The purchase price of the AffloVest business exceeded the net acquisition-date estimated fair value amounts of the identifiable assets acquired and the liabilities assumed by $31.1 million, which was assigned to goodwill. Intangible Assets Our patents and other intangible assets are summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ At September 30, 2021 ​ ​ Average ​ Gross ​ ​ ​ ​ ​ ​ Amortization ​ Carrying ​ Accumulated ​ Net (In thousands) Period ​ Amount ​ Amortization ​ Amount Definite-lived intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Patents ​ 12 years ​ $ 537 ​ $ 97 ​ $ 440 Defensive intangible assets ​ 3 years ​ ​ 1,125 ​ ​ 550 ​ ​ 575 Customer accounts ​ 2 years ​ ​ 125 ​ ​ 82 ​ ​ 43 Customer relationships ​ 13 years ​ ​ 31,000 ​ ​ 146 ​ ​ 30,854 Developed technology ​ 11 years ​ ​ 13,000 ​ ​ 72 ​ ​ 12,928 Subtotal ​ ​ ​ ​ 45,787 ​ ​ 947 ​ ​ 44,840 Unamortized intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Tradenames ​ ​ ​ ​ 9,500 ​ ​ — ​ ​ 9,500 Patents pending ​ ​ ​ ​ 630 ​ ​ — ​ ​ 630 Total intangible assets ​ ​ ​ $ 55,917 ​ $ 947 ​ $ 54,970 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ At December 31, 2020 ​ ​ Average ​ Gross ​ ​ ​ ​ ​ ​ Amortization ​ Carrying ​ Accumulated ​ Net (In thousands) Period ​ Amount ​ Amortization ​ Amount Definite-lived intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Patents ​ 11 years ​ $ 413 ​ $ 65 ​ $ 348 Defensive intangible assets ​ 4 years ​ ​ 1,125 ​ ​ 421 ​ ​ 704 Customer accounts ​ 2 years ​ 125 ​ 63 ​ 62 Subtotal ​ ​ ​ ​ 1,663 ​ ​ 549 ​ ​ 1,114 Unamortized intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Patents pending ​ ​ ​ ​ 566 ​ ​ — ​ ​ 566 Total intangible assets ​ ​ ​ $ 2,229 ​ $ 549 ​ $ 1,680 ​ Amortization expense was $0.3 million and $0.1 million for the three months ended September 30, 2021 and 2020, respectively, and $0.4 million and $0.3 million for the nine months ended September 30, 2021 and 2020, respectively. Future amortization expenses are expected as follows: ​ ​ ​ ​ ​ (In thousands) ​ ​ ​ 2021 (October 1 - December 31) ​ $ 953 2022 ​ ​ 3,811 2023 ​ 3,781 2024 ​ 3,759 2025 ​ 3,669 Thereafter ​ 28,867 Total ​ $ 44,840 ​

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2021
Accrued Expenses
Accrued Expenses	Note 8. Accrued Expenses Accrued expenses consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) At September 30, 2021 At December 31, 2020 Warranty ​ $ 1,779 ​ $ 1,606 In-transit inventory ​ ​ 1,341 ​ ​ 634 Legal and consulting ​ ​ 985 ​ ​ 882 Travel ​ 552 ​ 545 Clinical studies ​ ​ 135 ​ ​ 67 Sales and use tax ​ ​ 109 ​ ​ 193 Other ​ 449 ​ 496 Total ​ $ 5,350 ​ $ 4,423 ​

Warranty Reserves

Warranty Reserves	9 Months Ended
	Sep. 30, 2021
Warranty Reserves
Warranty Reserves	Note 9. Warranty Reserves The activity in the warranty reserve during and as of the end of the reporting periods presented was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, (In thousands) 2021 2020 2021 2020 Beginning balance ​ $ 5,117 ​ $ 4,208 ​ $ 4,841 ​ $ 3,759 Warranty provision ​ 624 ​ 820 ​ 2,080 ​ 2,097 Processed warranty claims ​ (604) ​ (514) ​ (1,784) ​ (1,342) Ending balance ​ $ 5,137 ​ $ 4,514 ​ $ 5,137 ​ $ 4,514 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued warranty reserve, current ​ $ 1,779 ​ $ 1,443 ​ $ 1,779 ​ $ 1,443 Accrued warranty reserve, non-current ​ ​ 3,358 ​ ​ 3,071 ​ ​ 3,358 ​ ​ 3,071 Total accrued warranty reserve ​ $ 5,137 ​ $ 4,514 ​ $ 5,137 ​ $ 4,514 ​

Credit Agreement

Credit Agreement	9 Months Ended
	Sep. 30, 2021
Credit Agreement
Credit Agreement	Note 10. Credit Agreement On August 3, 2018, we entered into a credit agreement with Wells Fargo Bank, National Association, which was amended by a First Amendment dated February 12, 2019, a Waiver and Second Amendment dated March 25, 2019, and a Third Amendment dated August 2, 2019 (collectively, the “2018 Credit Agreement”). On April 30, 2021, we entered into an Amended and Restated Credit Agreement (the “Restated Credit Agreement”) with the lenders from time to time party thereto, and Wells Fargo Bank, National Association, as Administrative Agent. The Restated Credit Agreement amended and restated in its entirety the 2018 Credit Agreement. On September 8, 2021, we entered into a First Amendment Agreement (the “Amendment”), which amends the Restated Credit Agreement (as amended by the Amendment, the “Credit Agreement”) with the lenders from time to time party thereto and Wells Fargo Bank, National Association, as administrative agent. The Amendment, among other things, adds a $30.0 million incremental term loan to the $25.0 million revolving credit facility provided by the Restated Credit Agreement. The term loan is reflected on our condensed consolidated financial statements as a note payable. The term loan and the revolving credit facility mature on September 8, 2024. The Credit Agreement provides that, subject to satisfaction of certain conditions, we may increase the amount of the revolving loans available under the Credit Agreement and/or add one or more term loan facilities in an amount not to exceed $25.0 million in the aggregate, such that the total aggregate principal amount of loans available under the Credit Agreement (including under the revolving credit facility) does not exceed $80.0 million. On September 8, 2021, in connection with the closing of the AffloVest Acquisition, we borrowed the $30.0 million term loan and utilized that borrowing, together with a draw of $25.0 million under the revolving credit facility and cash on hand, to fund the purchase price. ​ The principal of the term loan is required to be repaid in quarterly installments of $750,000 commencing January 7, 2022, through July 8, 2024, with the remaining outstanding balance due on September 8, 2024 . ​ The term loan and amounts drawn under the revolving credit facility bear interest, at our option, at a rate equal to (a) the highest of (i) the prime rate, (ii) the federal funds rate plus 0.50% and (iii) LIBOR for an interest period of one month plus 1% (the “Base Rate”) plus an applicable margin or (b) LIBOR for an interest period of one, three or six months, at our option, plus the applicable margin. The applicable margin is 0.75% to 2.25% on loans bearing interest at the Base Rate and 1.75% to 3.25% on loans bearing interest at LIBOR, in each case depending on our consolidated total leverage ratio. At September 30, 2021, all outstanding borrowings were subject to interest at a rate calculated at LIBOR plus an applicable margin equaling 2.8% . Undrawn portions of the revolving credit facility are subject to an unused line fee at a rate per annum from 0.300% to 0.375% , depending on our consolidated total leverage ratio. Maturities of the term loan for the next three years as of September 30, 2021, are as follows: ​ ​ ​ ​ ​ (In thousands) Amount 2021 (October 1 - December 31) ​ $ — 2022 ​ ​ 3,000 2023 ​ ​ 3,000 2024 ​ ​ 24,000 Total ​ $ 30,000 ​ Our obligations under the Credit Agreement are secured by a security interest in substantially all of our and our subsidiaries’ assets and are also guaranteed by our subsidiaries. The Credit Agreement contains a number of restrictions and covenants, including that we maintain compliance with a maximum leverage ratio, minimum fixed charge coverage ratio and a minimum consolidated EBITDA covenant. As of September 30, 2021, we were in compliance with all financial covenants under the Credit Agreement.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies
Commitments and Contingencies	Note 11. Commitments and Contingencies Lease Obligations We lease property and equipment under operating leases, typically with terms greater than 12 months , and determine if an arrangement contains a lease at inception. In general, an arrangement contains a lease if there is an identified asset and we have the right to direct the use of and obtain substantially all of the economic benefit from the use of the identified asset. We record an operating lease liability at the present value of lease payments over the lease term on the commencement date. The related right of use (“ROU”) operating lease asset reflects rental escalation clauses, as well as renewal options and/or termination options. The exercise of lease renewal and/or termination options are at our discretion and are included in the determination of the lease term and lease payment obligations when it is deemed reasonably certain that the option will be exercised. When available, we use the rate implicit in the lease to discount lease payments to present value; however, certain leases do not provide a readily determinable implicit rate. Therefore, we must estimate our incremental borrowing rate to discount the lease payments based on information available at lease commencement. We classify our leases as buildings, vehicles or computer and office equipment and do not separate lease and nonlease components of contracts for any of the aforementioned classifications. In accordance with applicable guidance, we do not record leases with terms that are less than one year on the Condensed Consolidated Balance Sheet. None of our lease agreements contain material restrictive covenants or residual value guarantees. Buildings We lease certain office and warehouse space at various locations in the United States where we provide services. These leases are typically greater than one year with fixed, escalating rents over the noncancelable terms and, therefore, ROU operating lease assets and operating lease liabilities are recorded on the Condensed Consolidated Balance Sheet, with rent expense to be recognized on a straight-line basis over the term of the lease. The remaining lease terms vary from approximately one to nine years as of September 30, 2021. We entered into a lease (“initial lease”) in October 2018, for approximately 80,000 square feet of office space for our new corporate headquarters in Minneapolis, Minnesota. In December 2018, we amended the initial lease to add approximately 29,000 square feet of additional office space, which is accounted for as a separate lease (“second lease”) in accordance with ASU No. 2016-02, “Leases” (Topic 842) (“ASC 842”). In December 2019, we further amended the lease which extended the expiration date of the initial lease, extended the expiration date of and added approximately 4,000 square feet to the second lease, as well as added approximately 37,000 square feet of additional office space, accounted for as a separate lease (“third lease”) in accordance with ASC 842. The portion of the space covered under the initial lease was placed in service in September 2019. This portion was recognized as an operating lease and included in the ROU operating lease assets and operating lease liabilities on the Condensed Consolidated Balance Sheets. The portion of the space covered under the second lease commenced in September 2020. Finally, the portion of the space covered under the third lease commenced in September 2021. Vehicles We lease vehicles for certain members of our field sales organization under a vehicle fleet program whereby the initial, noncancelable lease is for a term of 367 days , thus more than one year. Subsequent to the initial term, the lease becomes a month-to-month, cancelable lease. As of September 30, 2021, we had approximately 45 vehicles with agreements within the initial, noncancelable lease term that are recorded as ROU operating lease assets and operating lease liabilities. In addition to monthly rental fees specific to the vehicle, there are fixed monthly nonlease components that have been included in the ROU operating lease assets and operating lease liabilities. The nonlease components are not significant. Computer and Office Equipment We also have operating lease agreements for certain computer and office equipment. The remaining lease terms as of September 30, 2021, ranged from less than one year to approximately four years with fixed monthly payments that are included in the ROU operating lease assets and operating lease liabilities. The leases provide an option to purchase the related equipment at fair market value at the end of the lease. The leases will automatically renew as a month-to-month rental at the end of the lease if the equipment is not purchased or returned. Lease Position, Undiscounted Cash Flow and Supplemental Information The table below presents information related to our ROU operating lease assets and operating lease liabilities that we have recorded: ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) At September 30, 2021 At December 31, 2020 Right of use operating lease assets ​ $ 23,919 ​ $ 20,132 ​ ​ ​ ​ ​ ​ ​ Operating lease liabilities: ​ ​ ​ ​ ​ ​ Current ​ $ 2,412 ​ $ 2,006 Non-current ​ 23,357 ​ 19,388 Total ​ $ 25,769 ​ $ 21,394 ​ ​ ​ ​ ​ ​ ​ Operating leases: ​ ​ ​ ​ ​ ​ Weighted average remaining lease term ​ 8.9 years ​ ​ 9.4 years Weighted average discount rate ​ ​ 4.2% ​ ​ 4.4% ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, ​ ​ 2021 ​ 2020 Supplemental cash flow information for our operating leases: ​ ​ ​ ​ ​ ​ Cash paid for operating lease liabilities ​ $ 2,411 ​ $ 1,849 Non-cash right of use assets obtained in exchange for new operating lease obligations ​ $ 6,146 ​ $ 6,664 ​ The table below reconciles the undiscounted cash flows under the operating lease liabilities recorded on the Condensed Consolidated Balance Sheet for the periods presented: ​ ​ ​ ​ ​ (In thousands) ​ ​ ​ 2021 (October 1 - December 31) ​ $ 908 2022 ​ ​ 3,345 2023 ​ 3,274 2024 ​ 3,260 2025 ​ 3,359 Thereafter ​ 16,653 Total minimum lease payments ​ ​ 30,799 Less: Amount of lease payments representing interest ​ ​ (5,030) Present value of future minimum lease payments ​ ​ 25,769 Less: Current obligations under operating lease liabilities ​ ​ (2,412) Non-current obligations under operating lease liabilities ​ $ 23,357 ​ As of September 30, 2021, we have additional lease commitments of $0.8 million related to amendments to existing building leases that have not yet commenced. As the lessee we are involved in providing guidance to the lessor for related improvements, however these improvements are managed and owned by the lessor. Operating lease costs were $0.9 million and $0.8 million for the three months ended September 30, 2021 and 2020, respectively. Operating lease costs were $2.6 million and $2.1 million for the nine months ended September 30, 2021 and 2020, respectively. Major Vendors We had purchases from two vendors that accounted for 36% of our total purchases for the three months ended September 30, 2021. We had purchases from one vendor that accounted for 24% of our total purchases for the nine months ended September 30, 2021. We had purchases from two vendors that accounted for 31% and 33% of our total purchases for the three and nine months ended September 30, 2020, respectively. Purchase Commitments We issued purchase orders prior to September 30, 2021, totaling $28.4 million for goods that we expect to receive within the next year. Retirement Plan We maintain a 401(k) retirement plan for our employees in which eligible employees can contribute a percentage of their pre-tax compensation. We recorded an expense related to our discretionary contributions to the 401(k) plan of $0.3 million and $0.1 million for the three months ended September 30, 2021 and 2020, respectively, and $0.9 million and $0.2 million for the nine months ended September 30, 2021 and 2020, respectively. Legal Proceedings From time to time, we are subject to various claims and legal proceedings arising in the ordinary course of business. Regardless of outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. On February 13, 2019, we were served with a sealed amended complaint venued in the United States District Court for the Southern District of Texas, Houston Division, captioned United States ex rel Veterans First Medical Supply, LLC vs. Tactile Medical Systems Technology, Inc., Case No. 18-2871, which had been filed on January 23, 2019. The complaint is a qui tam action on behalf of the United States brought by one of our competitors. The United States has declined to intervene in this action. The complaint alleges that we violated the Federal Anti-Kickback Statute and the Federal False Claims Act, claiming that we submitted false claims and made false statements in connection with the Medicare and Medicaid programs, and that we engaged in unlawful retaliation in violation of the Federal False Claims Act. The complaint seeks damages, statutory penalties, attorneys’ fees, treble damages and costs. We filed a motion to dismiss on April 5, 2019. This motion was denied on February 21, 2020. On March 6, 2020, we filed our answer to the complaint and asserted counterclaims. On May 7, 2020, the plaintiff filed a motion to dismiss our counterclaims. On September 8, 2020, we filed a motion for Partial Summary Judgment. On January 2, 2021, the plaintiff filed a motion for Partial Summary Judgment. These motions were decided on March 29, 2021, wherein the court denied plaintiff’s motion to dismiss our counterclaims; granted our motion for Partial Summary Judgment and dismissed Counts I (standalone/direct violation of the Federal Anti-Kickback Statute) and III (violation of the retaliation provision of the Federal False Claims Act) of the complaint; and denied plaintiff’s motion for Partial Summary Judgment. As a result, the remaining allegations consist of those in Count II (violations of the Federal False Claims Act) of the complaint. On August 13, 2021, we filed a motion for summary judgement on the remaining Count II. Plaintiff filed a motion for summary judgement on the counterclaims. These motions are currently pending. We believe the plaintiff’s remaining allegations are without merit and we intend to continue to vigorously defend against the lawsuit. We and certain of our present or former officers were sued in a purported securities class action lawsuit that was filed in the United States District Court for the District of Minnesota on September 29, 2020, and that is pending under the caption Brian Mart v. Tactile Systems Technology, Inc., et al., File No. 0:20-cv-02074-NEB-BRT. On April 19, 2021, the plaintiff filed an Amended Complaint against us and eight of our present and former officers and directors. Plaintiff seeks to represent a class consisting of investors who purchased our common stock in the market during the time period from May 7, 2018 through June 8, 2020 (“alleged class period”). The Amended Complaint alleges the following claims under the Securities Exchange Act of 1934, as amended (the “Exchange Act”): (1) that we and certain officer defendants made materially false or misleading public statements about our business, operational and compliance policies, and results during the alleged class period in violation of Section 10(b) of the Exchange Act; (2) that we and the individual defendants engaged in a scheme to defraud investors in order to allow the individual defendants to sell our stock in violation of Section 10(b) of the Exchange Act; (3) that the individual defendants engaged in improper insider trading of our stock in violation of Section 20A of the Exchange Act; and (4) that we and the individual defendants are liable under Section 20(a) of the Exchange Act because each defendant is a controlling person. On June 18, 2021, we and the individual defendants filed a motion to dismiss the Amended Complaint. The motion has not been decided yet.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2021
Stockholders' Equity
Stockholders' Equity	Note 12. Stockholders' Equity Stock-Based Compensation Our 2016 Equity Incentive Plan (the “2016 Plan”) authorizes us to grant stock options, stock appreciation rights, restricted stock, stock units and other stock-based awards to employees, non-employee directors and certain consultants and advisors. There were up to 4,800,000 shares of our common stock initially reserved for issuance pursuant to the 2016 Plan. The 2016 Plan provides that the number of shares reserved and available for issuance under the 2016 Plan will automatically increase annually on January 1 of each calendar year, commencing in 2017 and ending on and including January 1, 2026, by an amount equal to the lesser of: (a) 5% of the number of common shares of stock outstanding as of December 31 of the immediately preceding calendar year, or (b) 2,500,000 shares; provided, however, that our Board of Directors may determine that any annual increase be a lesser number. In addition, all awards granted under our 2007 Omnibus Stock Plan and our 2003 Stock Option Plan that were outstanding when the 2016 Plan became effective and that are forfeited, expired, cancelled, settled for cash or otherwise not issued, will become available for issuance under the 2016 Plan. Pursuant to the automatic increase feature of the 2016 Plan, 972,591 and 952,697 shares were added as available for issuance thereunder on January 1, 2021 and 2020, respectively. As of September 30, 2021, 6,366,806 shares were available for future grant pursuant to the 2016 Plan. Upon adoption and approval of the 2016 Plan, all of our previous equity incentive compensation plans were terminated. However, existing awards under those plans continue to vest in accordance with the original vesting schedules and will expire at the end of their original terms. In the second fiscal quarter of 2020, our Board of Directors appointed a new President and Chief Executive Officer (“CEO”), effective June 8, 2020. In conjunction with the acceptance of the written offer, our CEO received both restricted stock units and stock option awards under our 2016 Plan during the third fiscal quarter of 2020 and the stock options have a seven year term. A portion of the awards vested on June 30, 2021, with the remaining portion of the awards vesting over a period of three years from the date of grant. Further, the stock options were valued at the date of grant using the Monte Carlo Simulation model due to a market condition that required that our stock price exceed $40.15 for 20 consecutive trading days during the term of the option in order to vest. This condition was satisfied in the first quarter of 2021 We recorded stock-based compensation expense of $2.6 million and $3.2 million for the three months ended September 30, 2021 and 2020, respectively, and $7.7 million and $8.3 million for the nine months ended September 30, 2021 and 2020, respectively. This expense was allocated as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, (In thousands) 2021 2020 2021 2020 Cost of revenue ​ $ 171 ​ $ 171 ​ $ 455 ​ $ 358 Sales and marketing expenses ​ ​ 1,081 ​ ​ 1,436 ​ ​ 2,979 ​ ​ 3,915 Research and development expenses ​ ​ 68 ​ ​ 87 ​ ​ 224 ​ ​ 269 Reimbursement, general and administrative expenses ​ ​ 1,268 ​ ​ 1,470 ​ ​ 4,045 ​ ​ 3,746 Total stock-based compensation expense ​ $ 2,588 ​ $ 3,164 ​ $ 7,703 ​ $ 8,288 ​ Stock Options Stock options issued to participants other than non-employees typically vest over three or four years and typically have a contractual term of seven or ten years . Stock-based compensation expense included in the Condensed Consolidated Statements of Operations for stock options was $1.0 million and $1.1 million for the three months ended September 30, 2021 and 2020, respectively, and $3.3 million and $3.0 million for the nine months ended September 30, 2021 and 2020, respectively. At September 30, 2021, there was approximately $6.4 million of total unrecognized pre-tax stock option expense under our equity compensation plans, which is expected to be recognized on a straight-line basis over a weighted-average period of 1.9 years. Our stock option activity for the nine months ended September 30, 2021, was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ Weighted- ​ ​ ​ ​ ​ ​ ​ Average ​ Average ​ Aggregate ​ ​ Options ​ Exercise Price ​ Remaining ​ Intrinsic (In thousands except options and per share data) ​ Outstanding ​ Per Share (1) ​ Contractual Life ​ Value (2) Balance at December 31, 2020 ​ 1,039,709 ​ $ 36.43 ​ 5.6 years ​ $ 13,381 Granted ​ 174,755 ​ $ 50.88 ​ ​ ​ ​ ​ Exercised ​ (138,586) ​ $ 25.85 ​ ​ ​ $ 3,863 Forfeited ​ (68,797) ​ $ 48.64 ​ ​ ​ ​ ​ Cancelled/Expired ​ (30,005) ​ $ 61.13 ​ ​ ​ ​ ​ Balance at September 30, 2021 ​ 977,076 ​ $ 38.90 ​ 5.2 years ​ $ 10,208 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options exercisable at September 30, 2021 ​ 508,184 ​ $ 30.45 ​ 4.4 years ​ $ 9,229 ​ (1) The exercise price of each option granted during the period shown was equal to the market price of the underlying stock on the date of grant. (2) The aggregate intrinsic value of options exercised represents the difference between the exercise price of the option and the closing stock price of our common stock on the date of exercise. The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period. Options exercisable of 461,138 as of September 30, 2020, had a weighted-average exercise price of $23.35 per share. Time-Based Restricted Stock Units We have granted time-based restricted stock units to certain participants under the 2016 Plan that are stock-settled with common shares. Time-based restricted stock units granted under the 2016 Plan vest over one to three years . Stock-based compensation expense included in the Condensed Consolidated Statements of Operations for time-based restricted stock units was $1.2 million and $1.4 million for the three months ended September 30, 2021 and 2020, respectively, and $3.7 million and $4.0 million for the nine months ended September 30, 2021 and 2020, respectively. At September 30, 2021, there was approximately $6.6 million of total unrecognized pre-tax compensation expense related to outstanding time-based restricted stock units that is expected to be recognized over a weighted-average period of 1.9 years. Our time-based restricted stock unit activity for the nine months ended September 30, 2021, was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ Average Grant Aggregate ​ ​ Units ​ Date Fair Value ​ Intrinsic (In thousands except unit and per unit data) ​ Outstanding ​ Per Unit ​ Value (1) Balance at December 31, 2020 ​ 211,469 ​ $ 48.29 ​ $ 9,503 Granted ​ 91,001 ​ $ 51.56 ​ ​ ​ Vested ​ (94,517) ​ $ 47.99 ​ ​ ​ Cancelled ​ (24,161) ​ $ 51.29 ​ ​ ​ Balance at September 30, 2021 ​ 183,792 ​ $ 49.66 ​ $ 8,170 ​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred and unissued at September 30, 2021 (2) ​ 6,469 ​ $ 38.94 ​ $ 288 ​ (1) The aggregate intrinsic value of restricted stock units outstanding was based on our closing stock price on the last trading day of the period. (2) For the nine months ended September 30, 2021, there were no restricted stock units granted to non-employee directors in lieu of their quarterly cash retainer payments. As of September 30, 2021, there were 6,469 outstanding restricted stock units that had been previously granted to non-employee directors in lieu of their quarterly cash retainer payments. Performance-Based Restricted Stock Units We have granted performance-based restricted stock units (“PSUs”) to certain participants under the 2016 Plan. These PSUs have both performance-based and time-based vesting features. The PSUs granted in 2018 were earned to the extent performance goals based on revenue and adjusted EBITDA were achieved in 2019. The PSUs granted in 2019 would have been earned to the extent performance goals based on revenue and adjusted EBITDA were achieved in 2020, but none were so earned. The PSUs granted in 2020 will be earned if and to the extent performance goals based on revenue and adjusted EBITDA are achieved in 2021. The PSUs granted in 2021 will be earned if and to the extent performance goals based on revenue and adjusted EBITDA are achieved in 2022. The number of PSUs earned will depend on the level at which the performance targets are achieved and can range from 50% of target if the minimum performance threshold is achieved and up to 150% of target if maximum performance is achieved. One-third of the earned PSUs will vest on the date the Compensation and Organization Committee certifies the number of PSUs earned, and the remaining two-thirds of the earned PSUs will vest on the first anniversary of that certification date. All earned and vested PSUs will be settled in shares of common stock. Stock-based compensation expense recognized for PSUs was an expense of $0.2 million and $0.4 million for the three months ended September 30, 2021 and 2020, respectively, and less than $0.1 million and $0.5 million for the nine months ended September 30, 2021 and 2020, respectively. The stock-based compensation expense for the nine months ended September 30, 2021 reflected a $0.5 million benefit due to a change in the estimated payout associated with PSUs granted in 2020 being below the minimum performance target threshold level, as defined, partially offset by an expense of $0.5 million related to the PSUs granted in 2018 and 2021. At September 30, 2021, there was approximately $1.5 million of total unrecognized pre-tax compensation expense related to outstanding PSUs that is expected to be recognized over a weighted average period of 2.4 years. Our performance-based restricted stock unit activity for the nine months ended September 30, 2021, was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Performance- ​ Weighted- ​ ​ ​ ​ Based Average Grant Aggregate ​ ​ Units ​ Date Fair Value ​ Intrinsic (In thousands except unit and per unit data) ​ Outstanding ​ Per Unit ​ Value (1) Balance at December 31, 2020 ​ 79,303 ​ $ 47.83 ​ $ 3,564 Granted ​ 39,419 ​ $ 51.82 ​ ​ ​ Vested ​ (34,159) ​ $ 33.98 ​ ​ ​ Cancelled ​ (23,936) ​ $ 65.43 ​ ​ ​ Balance at September 30, 2021 ​ 60,627 ​ $ 51.28 ​ $ 2,695 ​ (1) The aggregate intrinsic value of performance-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period. Employee Stock Purchase Plan Our employee stock purchase plan (“ESPP”), which was approved by our Board of Directors on April 27, 2016, and by our stockholders on June 20, 2016, allows participating employees to purchase shares of our common stock at a discount through payroll deductions. The ESPP is available to all of our employees and employees of participating subsidiaries. Participating employees may purchase common stock, on a voluntary after-tax basis, at a price equal to 85% of the lower of the closing market price per share of our common stock on the first or last trading day of each stock purchase period. The ESPP provides for six-month purchase periods, beginning on May 16 and November 16 of each calendar year. A total of 1,600,000 shares of common stock was initially reserved for issuance under the ESPP. This share reserve will automatically be supplemented each January 1, commencing in 2017 and ending on and including January 1, 2026, by an amount equal to the least of (a) 1% of the shares of our common stock outstanding on the immediately preceding December 31, (b) 500,000 shares or (c) such lesser amount as our Board of Directors may determine. Pursuant to the automatic increase feature of the ESPP, 194,518 and 190,539 shares were added as available for issuance thereunder on January 1, 2021 and 2020, respectively. As of September 30, 2021, 1,740,328 shares were available for future issuance under the ESPP. We recognized stock-based compensation expense associated with the ESPP of $ 0.2 million and $0.3 million for the three months ended September 30, 2021 and 2020, respectively, and $0.6 million and $0.8 million for the nine months ended September 30, 2021 and 2020, respectively.

Revenue

Revenue	9 Months Ended
	Sep. 30, 2021
Revenue
Revenue	​ ​ Note 13. Revenue We derive our revenue from the sale and rental of our products to our customers in the United States. The following table presents our revenue, inclusive of sales and rental revenue, disaggregated by product categories: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, (In thousands) 2021 ​ 2020 ​ 2021 ​ 2020 Revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Flexitouch system ​ $ 44,014 ​ $ 42,908 ​ $ 126,544 ​ $ 112,621 Entre system ​ 7,622 ​ 6,184 ​ 18,924 ​ 15,266 AffloVest ​ ​ 861 ​ ​ — ​ ​ 861 ​ ​ — Total ​ $ 52,497 ​ $ 49,092 ​ $ 146,329 ​ $ 127,887 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Percentage of total revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Flexitouch system ​ 84% ​ 87% ​ 86% ​ 88% Entre system ​ 14% ​ 13% ​ 13% ​ 12% AffloVest ​ ​ 2% ​ ​ — % ​ ​ 1% ​ ​ — % Total ​ 100% ​ 100% ​ 100% ​ 100% ​ Our revenue by channel, inclusive of sales and rental revenue, for the three and nine months ended September 30, 2021 and 2020, are summarized in the following table: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, (In thousands) 2021 ​ 2020 ​ 2021 ​ 2020 Private insurers and other payers ​ $ 36,034 ​ $ 34,554 ​ $ 99,665 ​ $ 90,459 Veterans Administration ​ ​ 6,737 ​ ​ 6,788 ​ ​ 19,905 ​ ​ 18,168 Medicare ​ ​ 8,865 ​ ​ 7,750 ​ ​ 25,898 ​ ​ 19,260 Durable medical equipment distributors ​ ​ 861 ​ ​ — ​ ​ 861 ​ ​ — Total ​ $ 52,497 ​ $ 49,092 ​ $ 146,329 ​ $ 127,887 ​ Our rental revenue is derived from rent-to-purchase arrangements that typically range from three to ten months. As title transfers to the patient, with whom we have the contract, upon the termination of the lease term and because collectability is probable, under ASC 842, these are recognized as sales-type leases. Each rental agreement contains two components, the controller and related garments, both of which are interdependent and recognized as one lease component. The revenue and associated cost of revenue of sales-type leases are recognized on the lease commencement date and a net investment in leases is recorded on the Condensed Consolidated Balance Sheet. We bill the patients’ insurance payers monthly over the duration of the rental term. We record the net investment in leases and recognize revenue upon commencement of the lease in the amount of the expected consideration to be received through the monthly payments. Similar to our sales revenue, the transaction price is impacted by multiple factors, including the terms and conditions contracted by third party payers. As the rental contract resides with the patients, we have elected the portfolio approach, at the payer level, to determine the expected consideration, which considers the impact of early terminations. While the contract is with the patient, in certain circumstances, the third party payer elects an initial rental period with an option to extend. We assess the likelihood of extending the lease at the onset of the lease to determine if the option is reasonably certain to be exercised. As the lease is short-term in nature, we anticipate collection of substantially all of the net investment within the first year of the lease agreement. Completion of these payments represents the fair market value of the equipment, and as such, interest income is not applicable. Rental revenue for the three and nine months ended September 30, 2021 and 2020, was primarily from private insurers. Sales-type lease revenue and the associated cost of revenue for the three and nine months ended September 30, 2021 and 2020, was: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, (In thousands) ​ 2021 ​ 2020 ​ 2021 ​ 2020 Sales-type lease revenue ​ $ 8,037 ​ $ 6,519 ​ $ 22,114 ​ $ 18,173 Cost of sales-type lease revenue ​ 2,433 ​ 2,562 ​ 6,501 ​ 6,062 Gross profit ​ $ 5,604 ​ $ 3,957 ​ $ 15,613 ​ $ 12,111 ​

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2021
Income Taxes
Income Taxes	Note 14. Income Taxes We record our interim provision for income taxes by applying our estimated annual effective tax rate to our year-to-date pre-tax income and adjusting for discrete tax items recorded in the period. Deferred income taxes result from temporary differences between the reporting of amounts for financial statement purposes and income tax purposes. These differences relate primarily to different methods used for income tax reporting purposes, including for depreciation and amortization, warranty and vacation accruals, and deductions related to allowances for doubtful accounts receivable and inventory reserves. Our provision for income taxes included current federal and state income tax expense, as well as deferred federal and state income tax expense. The effective tax rate for the three months ended September 30, 2021, was an expense of 126% , compared to a benefit of 55% for the three months ended September 30, 2020. The primary driver of the change in our effective tax rate is primarily attributable to a change in projected taxable income. We recorded an income tax expense of $1.9 million and a benefit of $0.8 million for the three months ended September 30, 2021 and 2020, respectively. ​ The effective tax rate for the nine months ended September 30, 2021, was a benefit of 24% , compared to an expense of 17% for the nine months ended September 30, 2020. The primary driver of the change in our effective tax rate is attributable to recording a benefit in the nine months ended September 30, 2021, to recognize a tax credit for a research and development credit study conducted for tax years 2017-2020 as well as a change in deductibility of business meals to 100% in 2021 compared to 50% in 2020. We recorded an income tax benefit of $1.4 million and an expense of $2.3 million for the nine months ended September 30, 2021 and 2020, respectively. We recognize the financial statement benefit of a tax position only after determining that the relevant tax authority is more-likely-than-not to sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the condensed consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. As of September 30, 2021, tax contingencies related to federal and state credits recorded within the Condensed Consolidated Balance Sheets were $0.5 million. Changes in tax laws, regulations, administrative practices, principles, and interpretations may impact our tax contingencies. The timing of the resolution of income tax controversies is highly uncertain, and the amounts ultimately paid, if any, upon resolution of the issues raised by the taxing authorities may differ from the amounts accrued. We are currently under examination by the New York Department of Taxation and Finance for tax years 2017, 2018, and 2019. The examination may lead to proposed adjustments to our taxes or our net operating losses with respect to years under examination as well as subsequent periods. In the event of any future tax assessments, we have elected to record the income taxes and any related interest and penalties as income tax expense on our statement of operations.

Net (Loss) Income Per Share

Net (Loss) Income Per Share	9 Months Ended
	Sep. 30, 2021
Net (Loss) Income Per Share
Net Income (Loss) Per Share	Note 15. Net (Loss) Income Per Share The following table sets forth the computation of our basic and diluted net (loss) income per share: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, (In thousands, except share and per share data) 2021 2020 2021 2020 Net (loss) income ​ $ (3,355) ​ $ 2,424 ​ $ (4,316) ​ $ (12,733) Weighted-average shares outstanding ​ ​ 19,790,838 ​ ​ 19,415,640 ​ ​ 19,676,749 ​ ​ 19,309,344 Dilutive effect of stock-based awards ​ ​ — ​ ​ 331,725 ​ ​ — ​ ​ — Weighted-average shares used to compute diluted net (loss) income per share ​ ​ 19,790,838 ​ ​ 19,747,365 ​ ​ 19,676,749 ​ ​ 19,309,344 Net (loss) income per share - Basic ​ $ (0.17) ​ $ 0.12 ​ $ (0.22) ​ $ (0.66) Net (loss) income per share - Diluted ​ $ (0.17) ​ $ 0.12 ​ $ (0.22) ​ $ (0.66) ​ The following common stock equivalents were excluded from the computation of diluted net (loss) income per share for the periods presented because including them would have been anti-dilutive: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Restricted stock units ​ 190,261 ​ 104,786 ​ 190,261 ​ 223,776 Common stock options ​ 977,076 ​ 594,117 ​ 977,076 ​ 982,182 Performance stock units ​ 60,627 ​ 38,666 ​ 60,627 ​ 113,646 Employee stock purchase plan ​ 38,325 ​ 60,196 ​ 33,931 ​ 48,360 Total ​ 1,266,289 ​ 797,765 ​ 1,261,895 ​ 1,367,964 ​

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Fair Value Measurements
Fair Value Measurements	Note 16. Fair Value Measurements We determine the fair value of our assets and liabilities based on the exchange price that would be received for an asset or paid to transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value maximize the use of observable inputs and minimize the use of unobservable inputs. We use a fair value hierarchy with three levels of inputs, of which the first two are considered observable and the last unobservable, to measure fair value. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets or liabilities (Level 1). The next highest priority is based on quoted prices for similar assets or liabilities in active markets or quoted prices for identical or similar assets or liabilities in non-active markets or other observable inputs (Level 2). The lowest priority is given to unobservable inputs (Level 3). As of September 30, 2021, we no longer had any money market mutal funds. The following provides information regarding fair value measurements for our cash equivalents as of December 31, 2020, according to the three-level fair value hierarchy: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2020 ​ Quoted Prices ​ ​ ​ ​ ​ ​ ​ ​ in Active ​ Significant ​ ​ ​ ​ ​ ​ ​ ​ Markets for ​ Other ​ Significant ​ ​ ​ ​ Identical ​ Observable ​ Unobservable ​ ​ ​ ​ Assets ​ Inputs ​ Inputs ​ ​ (In thousands) ​ (Level 1) ​ (Level 2) ​ (Level 3) ​ Total Recurring Fair Value Measurements: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market mutual funds ​ $ 16,188 ​ $ — ​ $ — ​ $ 16,188 Total ​ $ 16,188 ​ $ — ​ $ — ​ $ 16,188 ​ During the three and nine months ended September 30, 2021, there were no transfers within the three-level hierarchy. A significant transfer is recognized when the inputs used to value a security have been changed, which merits a transfer between the disclosed levels of the valuation hierarchy. The fair value of our money market mutual funds is determined based on valuations provided by external investment managers who obtain them from a variety of industry standard data providers. The carrying amounts of financial instruments such as cash equivalents, accounts receivable, other assets, accounts payable, accrued expenses and other liabilities approximate their related fair values due to the short-term maturities of these items. Non-financial assets, such as equipment and leasehold improvements, and intangible assets are subject to non-recurring fair value measurements if they are deemed impaired. As of June 30, 2020, we re-measured the value of our intangible assets related to the Airwear wrap product line to their fair value, which was deemed to be $0 . We have obligations to pay up to $20.0 million in earn-out payments in cash if certain future financial results of the AffloVest business are met. The earn-out liability was valued using Level 3 inputs. The fair value of the earn-out was determined by employing a Monte Carlo Simulation model in a risk-neutral framework. The underlying simulated variable includes recognized revenue. The recognized revenue volatility estimate was based on a study of historical asset volatility for a set of comparable public companies. The model includes other assumptions including the market price of risk, which was calculated as the weighted average cost of capital less the long-term risk free rate. ​

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Summary of Significant Accounting Policies
Basis of Presentation	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial reporting and pursuant to the rules and regulations of the SEC. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments (including those which are normal and recurring) considered necessary for a fair presentation of the interim financial information have been included. The results for the nine months ended September 30, 2021, are not necessarily indicative of results to be expected for the year ending December 31, 2021, or for any other interim period or for any future year. The condensed consolidated interim financial statements should be read in conjunction with the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2020.
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements include the accounts of Tactile Systems Technology, Inc. and its wholly owned subsidiary, Swelling Solutions, Inc. All intercompany balances and transactions have been eliminated in consolidation.
Risks and Uncertainties	Risks and Uncertainties Coronavirus (COVID-19) The United States economy in general and our business specifically have been negatively affected by the COVID-19 pandemic. We have seen adverse impacts as it relates to the decline in the number of patients that healthcare facilities and clinics are able to treat due to enhanced safety protocols, particularly during 2020 and the first quarter of 2021. While we saw some level of recovery in the second quarter of 2021, the third quarter was negatively impacted by the prolonged recovery from COVID-19 and increased Delta variant cases during the period, which resulted in restricted access to clinics and hospitals and disrupted the recovery in patient visits versus the pre-COVID environment. There are no reliable estimates of how long the pandemic will last, whether any recovery will be sustained or will reverse course, the severity of any resurgence of COVID-19 or variant strains of the virus, the effectiveness of vaccines and attitudes towards receiving them, or what ultimate effects the pandemic will have. For that reason, we are unable to reasonably estimate the long-term impact of the pandemic on our business at this time. Since the onset of COVID-19, we have remained proactive to ensure we continue to adapt to the needs of our employees, clinicians and patients . We cannot assure you that these changes to our processes and practices will be successful in mitigating the impact of COVID-19 on our business. We continue to evaluate and, if appropriate, will adopt other measures in the future related to the ongoing safety of our employees, clinicians and patients. In addition, we are closely monitoring mandatory vaccination requirements and related evolving guidance that is or may be applicable to us, including in our capacity as a U.S. government contractor. See See Part II, I tem 1A. “ Risk Factors” in this Form 10-Q for additional information about vaccine mandates and potential risks related thereto.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and to disclose contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Comprehensive (Loss) Income	Comprehensive (Loss) Income Comprehensive (loss) income reflects the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive (loss) income represents net (loss) income adjusted for unrealized gains and losses on available-for-sale marketable securities and the related taxes.
Business Segments	Business Segments We operate and report in only one operating and reportable segment. Our chief operating decision maker does not use financial information below revenue to allocate resources.
Goodwill	Goodwill Goodwill represents the excess of the purchase price paid over the estimated fair value of the net assets acquired and liabilities assumed in the acquisition of a business. Goodwill is not amortized, but is tested for impairment at least annually or on an interim basis if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. We plan to perform our annual assessment of goodwill for impairment as of July 1st of each fiscal year. See Note 7 – “Goodwill and Intangible Assets” for additional information.
Revenue Recognition for AffloVest	Revenue Recognition for AffloVest The AffloVest device is sold through home medical equipment and durable medical equipment providers (collectively, "distributors"). Revenue is recognized when control of the promised goods or services is transferred to the distributors, in an amount that reflects the consideration we expect to be entitled to in exchange for transferring those goods or providing services. We account for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. When determining whether the distributor has obtained control of the goods or services, we consider any future performance obligations. Generally, there is no post-shipment obligation on products sold other than warranty obligations in the normal and ordinary course of business. ​ In general, revenue from the sale of the AffloVest product is recognized at shipment, unless circumstances dictate that control has not yet passed to the distributor. ​ Certain of our contracts include volume-based incentives which involve rebates that are negotiated at or prior to the time of sale with the customer and are redeemable only if the customer achieves a specified cumulative level of sales or sales increase. Under these incentive programs, at the time of sale, we determine the most likely amount of the rebate to be paid based on forecasted sales levels. These forecasts are updated at least quarterly for each customer, and the transaction price is reduced for the anticipated cost of the rebate. If the forecasted sales for a customer change, the accrual for rebates is adjusted to reflect the new rebates expected to be earned by the customer. ​ Amounts billed to customers for shipping and handling activities after the customer obtains control are treated as a promised service performance obligation and recorded in revenue in the accompanying Consolidated Statements of Operations. Shipping and handling costs incurred for the delivery of goods to customers are considered a cost to fulfill the contract and are included in cost of revenue sold in the accompanying Consolidated Statements of Operations. ​ For a description of our revenue recognition policies related to our Flexitouch and Entre systems, see Note 3 – “Summary of Significant Accounting Policies” to the consolidated financial statements in our Annual Report on Form 10-K for the year ended December 31, 2020. ​
Accounting Pronouncement Not Yet Adopted	Accounting Pronouncement Not Yet Adopted In March 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2020-04, “Reference Rate Reform (Topic 848) — Facilitation of the Effect of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”), addressing the discontinuation of LIBOR, a widely used reference rate for pricing financial products. The ASU is intended to provide optional expedients and exceptions if certain criteria are met when accounting for contracts, hedging relationships and other transactions that reference LIBOR, or another reference rate expected to be discontinued because of reference rate reform. The application and adoption requirements of ASU 2020-04 are optional until December 31, 2022 and vary based on expedients elected. We have not elected any expedients to date and are currently evaluating any potential future impacts on the condensed consolidated financial statements.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements In December 2019, the FASB issued ASU No. 2019-12, “Income Taxes (Topic 740) — Simplifying the Accounting for Income Taxes” (“ASU 2019-12”), which is intended to simplify various aspects of the accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. We adopted ASU 2019-12 as of January 1, 2021, and it did not have an impact on the condensed consolidated financial statements. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments — Credit Losses” (“ASU 2016-13”), which introduced a new model for recognizing credit losses on financial instruments based on an estimate of the current expected credit losses. The new current expected credit losses (“CECL”) model generally calls for the immediate recognition of all expected credit losses and applies to financial instruments and other assets, including accounts receivable and other financial assets measured at amortized cost, debt securities and other financial assets. This guidance replaced the previous incurred loss model for measuring expected credit losses and requires expected losses on available-for-sale debt securities to be recognized through an allowance for credit losses rather than as reductions in the amortized cost of the securities. We adopted ASU 2016-13 as of January 1, 2020, and it did not have an impact on the consolidated financial statements at that time. In connection with the AffloVest Acquisition, it was determined CECL did not have a material financial impact on the receivables related to the durable medical equipment channel.

Acquisitions (Tables)

Acquisitions (Tables)	9 Months Ended
	Sep. 30, 2021
Acquisitions
Summary of purchase price allocation	The following table summarizes the purchase price allocation: ​ ​ ​ ​ (In millions) Allocated Fair Value Inventories ​ $ 1.6 Property and equipment (1) ​ ​ — Intangible assets ​ ​ 53.5 Goodwill ​ ​ 31.1 Purchase price ​ $ 86.2 ​ (1) The purchase price included less than $0.1 million of property and equipment.
Schedule of allocation of purchase price	​ The following table reflects the allocation of purchase price to the acquired intangible assets and related estimated useful lives: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (In millions) Allocated Fair Value ​ Estimated Useful Life Customer relationships ​ $ 31.0 ​ 13 years Developed technology ​ ​ 13.0 ​ 11 years Tradenames ​ 9.5 ​ Indefinite Total intangible assets ​ $ 53.5 ​ ​
Schedule of condensed consolidated statements of operations reflect AffoVest operations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, (In thousands) 2021 ​ 2020 ​ 2021 ​ 2020 Total revenue ​ $ 56,249 ​ $ 53,068 ​ $ 157,686 ​ $ 139,130 Net income (loss) ​ $ 628 ​ $ (309) ​ $ 1,369 ​ $ 1,770 ​

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2021
Inventories
Schedule of inventories	​ ​ ​ ​ ​ ​ ​ ​ (In thousands) At September 30, 2021 At December 31, 2020 Finished goods ​ $ 9,607 ​ $ 7,129 Component parts and work-in-process ​ 14,223 ​ 11,434 Total inventories ​ $ 23,830 ​ $ 18,563

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2021
Intangible Assets
Schedule of finite lived intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ At September 30, 2021 ​ ​ Average ​ Gross ​ ​ ​ ​ ​ ​ Amortization ​ Carrying ​ Accumulated ​ Net (In thousands) Period ​ Amount ​ Amortization ​ Amount Definite-lived intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Patents ​ 12 years ​ $ 537 ​ $ 97 ​ $ 440 Defensive intangible assets ​ 3 years ​ ​ 1,125 ​ ​ 550 ​ ​ 575 Customer accounts ​ 2 years ​ ​ 125 ​ ​ 82 ​ ​ 43 Customer relationships ​ 13 years ​ ​ 31,000 ​ ​ 146 ​ ​ 30,854 Developed technology ​ 11 years ​ ​ 13,000 ​ ​ 72 ​ ​ 12,928 Subtotal ​ ​ ​ ​ 45,787 ​ ​ 947 ​ ​ 44,840 Unamortized intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Tradenames ​ ​ ​ ​ 9,500 ​ ​ — ​ ​ 9,500 Patents pending ​ ​ ​ ​ 630 ​ ​ — ​ ​ 630 Total intangible assets ​ ​ ​ $ 55,917 ​ $ 947 ​ $ 54,970 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ At December 31, 2020 ​ ​ Average ​ Gross ​ ​ ​ ​ ​ ​ Amortization ​ Carrying ​ Accumulated ​ Net (In thousands) Period ​ Amount ​ Amortization ​ Amount Definite-lived intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Patents ​ 11 years ​ $ 413 ​ $ 65 ​ $ 348 Defensive intangible assets ​ 4 years ​ ​ 1,125 ​ ​ 421 ​ ​ 704 Customer accounts ​ 2 years ​ 125 ​ 63 ​ 62 Subtotal ​ ​ ​ ​ 1,663 ​ ​ 549 ​ ​ 1,114 Unamortized intangible assets: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Patents pending ​ ​ ​ ​ 566 ​ ​ — ​ ​ 566 Total intangible assets ​ ​ ​ $ 2,229 ​ $ 549 ​ $ 1,680
Schedule of future amortization expense	​ ​ ​ ​ ​ (In thousands) ​ ​ ​ 2021 (October 1 - December 31) ​ $ 953 2022 ​ ​ 3,811 2023 ​ 3,781 2024 ​ 3,759 2025 ​ 3,669 Thereafter ​ 28,867 Total ​ $ 44,840

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2021
Accrued Expenses
Schedule of Accrued Expenses	​ ​ ​ ​ ​ ​ ​ ​ (In thousands) At September 30, 2021 At December 31, 2020 Warranty ​ $ 1,779 ​ $ 1,606 In-transit inventory ​ ​ 1,341 ​ ​ 634 Legal and consulting ​ ​ 985 ​ ​ 882 Travel ​ 552 ​ 545 Clinical studies ​ ​ 135 ​ ​ 67 Sales and use tax ​ ​ 109 ​ ​ 193 Other ​ 449 ​ 496 Total ​ $ 5,350 ​ $ 4,423

Warranty Reserves (Tables)

Warranty Reserves (Tables)	9 Months Ended
	Sep. 30, 2021
Warranty Reserves
Schedule of warranty reserves	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, (In thousands) 2021 2020 2021 2020 Beginning balance ​ $ 5,117 ​ $ 4,208 ​ $ 4,841 ​ $ 3,759 Warranty provision ​ 624 ​ 820 ​ 2,080 ​ 2,097 Processed warranty claims ​ (604) ​ (514) ​ (1,784) ​ (1,342) Ending balance ​ $ 5,137 ​ $ 4,514 ​ $ 5,137 ​ $ 4,514 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Accrued warranty reserve, current ​ $ 1,779 ​ $ 1,443 ​ $ 1,779 ​ $ 1,443 Accrued warranty reserve, non-current ​ ​ 3,358 ​ ​ 3,071 ​ ​ 3,358 ​ ​ 3,071 Total accrued warranty reserve ​ $ 5,137 ​ $ 4,514 ​ $ 5,137 ​ $ 4,514

Credit Agreement (Tables)

Credit Agreement (Tables)	9 Months Ended
	Sep. 30, 2021
Credit Agreement
Schedule of maturities of the term note payable	​ ​ ​ ​ ​ (In thousands) Amount 2021 (October 1 - December 31) ​ $ — 2022 ​ ​ 3,000 2023 ​ ​ 3,000 2024 ​ ​ 24,000 Total ​ $ 30,000

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies
Summary of lease-related assets and liabilities	​ ​ ​ ​ ​ ​ ​ ​ (In thousands) At September 30, 2021 At December 31, 2020 Right of use operating lease assets ​ $ 23,919 ​ $ 20,132 ​ ​ ​ ​ ​ ​ ​ Operating lease liabilities: ​ ​ ​ ​ ​ ​ Current ​ $ 2,412 ​ $ 2,006 Non-current ​ 23,357 ​ 19,388 Total ​ $ 25,769 ​ $ 21,394 ​ ​ ​ ​ ​ ​ ​ Operating leases: ​ ​ ​ ​ ​ ​ Weighted average remaining lease term ​ 8.9 years ​ ​ 9.4 years Weighted average discount rate ​ ​ 4.2% ​ ​ 4.4% ​ ​ ​ ​ ​ ​ ​ ​ ​ Nine Months Ended September 30, ​ ​ 2021 ​ 2020 Supplemental cash flow information for our operating leases: ​ ​ ​ ​ ​ ​ Cash paid for operating lease liabilities ​ $ 2,411 ​ $ 1,849 Non-cash right of use assets obtained in exchange for new operating lease obligations ​ $ 6,146 ​ $ 6,664 ​
Summary of undiscounted cash flows	​ ​ ​ ​ ​ (In thousands) ​ ​ ​ 2021 (October 1 - December 31) ​ $ 908 2022 ​ ​ 3,345 2023 ​ 3,274 2024 ​ 3,260 2025 ​ 3,359 Thereafter ​ 16,653 Total minimum lease payments ​ ​ 30,799 Less: Amount of lease payments representing interest ​ ​ (5,030) Present value of future minimum lease payments ​ ​ 25,769 Less: Current obligations under operating lease liabilities ​ ​ (2,412) Non-current obligations under operating lease liabilities ​ $ 23,357

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	9 Months Ended
	Sep. 30, 2021
Schedule of allocation of total stock-based compensation expense	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, (In thousands) 2021 2020 2021 2020 Cost of revenue ​ $ 171 ​ $ 171 ​ $ 455 ​ $ 358 Sales and marketing expenses ​ ​ 1,081 ​ ​ 1,436 ​ ​ 2,979 ​ ​ 3,915 Research and development expenses ​ ​ 68 ​ ​ 87 ​ ​ 224 ​ ​ 269 Reimbursement, general and administrative expenses ​ ​ 1,268 ​ ​ 1,470 ​ ​ 4,045 ​ ​ 3,746 Total stock-based compensation expense ​ $ 2,588 ​ $ 3,164 ​ $ 7,703 ​ $ 8,288
Schedule of stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ Weighted- ​ ​ ​ ​ ​ ​ ​ Average ​ Average ​ Aggregate ​ ​ Options ​ Exercise Price ​ Remaining ​ Intrinsic (In thousands except options and per share data) ​ Outstanding ​ Per Share (1) ​ Contractual Life ​ Value (2) Balance at December 31, 2020 ​ 1,039,709 ​ $ 36.43 ​ 5.6 years ​ $ 13,381 Granted ​ 174,755 ​ $ 50.88 ​ ​ ​ ​ ​ Exercised ​ (138,586) ​ $ 25.85 ​ ​ ​ $ 3,863 Forfeited ​ (68,797) ​ $ 48.64 ​ ​ ​ ​ ​ Cancelled/Expired ​ (30,005) ​ $ 61.13 ​ ​ ​ ​ ​ Balance at September 30, 2021 ​ 977,076 ​ $ 38.90 ​ 5.2 years ​ $ 10,208 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Options exercisable at September 30, 2021 ​ 508,184 ​ $ 30.45 ​ 4.4 years ​ $ 9,229 ​ (1) The exercise price of each option granted during the period shown was equal to the market price of the underlying stock on the date of grant. (2) The aggregate intrinsic value of options exercised represents the difference between the exercise price of the option and the closing stock price of our common stock on the date of exercise. The aggregate intrinsic value of options outstanding represents the difference between the exercise price of the option and the closing stock price of our common stock on the last trading day of the period.
Time-Based Restricted Stock Units
Schedule of stock-settled restricted stock unit activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted- ​ ​ ​ ​ ​ Average Grant Aggregate ​ ​ Units ​ Date Fair Value ​ Intrinsic (In thousands except unit and per unit data) ​ Outstanding ​ Per Unit ​ Value (1) Balance at December 31, 2020 ​ 211,469 ​ $ 48.29 ​ $ 9,503 Granted ​ 91,001 ​ $ 51.56 ​ ​ ​ Vested ​ (94,517) ​ $ 47.99 ​ ​ ​ Cancelled ​ (24,161) ​ $ 51.29 ​ ​ ​ Balance at September 30, 2021 ​ 183,792 ​ $ 49.66 ​ $ 8,170 ​ ​ ​ ​ ​ ​ ​ ​ ​ Deferred and unissued at September 30, 2021 (2) ​ 6,469 ​ $ 38.94 ​ $ 288 ​ (1) The aggregate intrinsic value of restricted stock units outstanding was based on our closing stock price on the last trading day of the period. (2) For the nine months ended September 30, 2021, there were no restricted stock units granted to non-employee directors in lieu of their quarterly cash retainer payments. As of September 30, 2021, there were 6,469 outstanding restricted stock units that had been previously granted to non-employee directors in lieu of their quarterly cash retainer payments.
Performance-based stock-settled restricted stock units
Schedule of stock-settled restricted stock unit activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Performance- ​ Weighted- ​ ​ ​ ​ Based Average Grant Aggregate ​ ​ Units ​ Date Fair Value ​ Intrinsic (In thousands except unit and per unit data) ​ Outstanding ​ Per Unit ​ Value (1) Balance at December 31, 2020 ​ 79,303 ​ $ 47.83 ​ $ 3,564 Granted ​ 39,419 ​ $ 51.82 ​ ​ ​ Vested ​ (34,159) ​ $ 33.98 ​ ​ ​ Cancelled ​ (23,936) ​ $ 65.43 ​ ​ ​ Balance at September 30, 2021 ​ 60,627 ​ $ 51.28 ​ $ 2,695 ​ (1) The aggregate intrinsic value of performance-based restricted stock units outstanding was based on our closing stock price on the last trading day of the period.

Revenue (Tables)

Revenue (Tables)	9 Months Ended
	Sep. 30, 2021
Revenue
Summary of revenue disaggregated by product	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, (In thousands) 2021 ​ 2020 ​ 2021 ​ 2020 Revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Flexitouch system ​ $ 44,014 ​ $ 42,908 ​ $ 126,544 ​ $ 112,621 Entre system ​ 7,622 ​ 6,184 ​ 18,924 ​ 15,266 AffloVest ​ ​ 861 ​ ​ — ​ ​ 861 ​ ​ — Total ​ $ 52,497 ​ $ 49,092 ​ $ 146,329 ​ $ 127,887 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Percentage of total revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Flexitouch system ​ 84% ​ 87% ​ 86% ​ 88% Entre system ​ 14% ​ 13% ​ 13% ​ 12% AffloVest ​ ​ 2% ​ ​ — % ​ ​ 1% ​ ​ — % Total ​ 100% ​ 100% ​ 100% ​ 100% ​
Summary of revenue by channel	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, (In thousands) 2021 ​ 2020 ​ 2021 ​ 2020 Private insurers and other payers ​ $ 36,034 ​ $ 34,554 ​ $ 99,665 ​ $ 90,459 Veterans Administration ​ ​ 6,737 ​ ​ 6,788 ​ ​ 19,905 ​ ​ 18,168 Medicare ​ ​ 8,865 ​ ​ 7,750 ​ ​ 25,898 ​ ​ 19,260 Durable medical equipment distributors ​ ​ 861 ​ ​ — ​ ​ 861 ​ ​ — Total ​ $ 52,497 ​ $ 49,092 ​ $ 146,329 ​ $ 127,887
Sales-type lease revenue and the associated cost of goods sold	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended September 30, ​ Nine Months Ended September 30, (In thousands) ​ 2021 ​ 2020 ​ 2021 ​ 2020 Sales-type lease revenue ​ $ 8,037 ​ $ 6,519 ​ $ 22,114 ​ $ 18,173 Cost of sales-type lease revenue ​ 2,433 ​ 2,562 ​ 6,501 ​ 6,062 Gross profit ​ $ 5,604 ​ $ 3,957 ​ $ 15,613 ​ $ 12,111

Net (Loss) Income Per Share (Ta

Net (Loss) Income Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Net (Loss) Income Per Share
Schedule of computation of the basic and diluted net (loss) income per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, (In thousands, except share and per share data) 2021 2020 2021 2020 Net (loss) income ​ $ (3,355) ​ $ 2,424 ​ $ (4,316) ​ $ (12,733) Weighted-average shares outstanding ​ ​ 19,790,838 ​ ​ 19,415,640 ​ ​ 19,676,749 ​ ​ 19,309,344 Dilutive effect of stock-based awards ​ ​ — ​ ​ 331,725 ​ ​ — ​ ​ — Weighted-average shares used to compute diluted net (loss) income per share ​ ​ 19,790,838 ​ ​ 19,747,365 ​ ​ 19,676,749 ​ ​ 19,309,344 Net (loss) income per share - Basic ​ $ (0.17) ​ $ 0.12 ​ $ (0.22) ​ $ (0.66) Net (loss) income per share - Diluted ​ $ (0.17) ​ $ 0.12 ​ $ (0.22) ​ $ (0.66)
Schedule of potentially dilutive securities outstanding	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Nine Months Ended ​ ​ September 30, ​ September 30, ​ 2021 2020 2021 2020 Restricted stock units ​ 190,261 ​ 104,786 ​ 190,261 ​ 223,776 Common stock options ​ 977,076 ​ 594,117 ​ 977,076 ​ 982,182 Performance stock units ​ 60,627 ​ 38,666 ​ 60,627 ​ 113,646 Employee stock purchase plan ​ 38,325 ​ 60,196 ​ 33,931 ​ 48,360 Total ​ 1,266,289 ​ 797,765 ​ 1,261,895 ​ 1,367,964

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Measurements
Schedule of fair value measurements for our cash equivalents and marketable securities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ At December 31, 2020 ​ Quoted Prices ​ ​ ​ ​ ​ ​ ​ ​ in Active ​ Significant ​ ​ ​ ​ ​ ​ ​ ​ Markets for ​ Other ​ Significant ​ ​ ​ ​ Identical ​ Observable ​ Unobservable ​ ​ ​ ​ Assets ​ Inputs ​ Inputs ​ ​ (In thousands) ​ (Level 1) ​ (Level 2) ​ (Level 3) ​ Total Recurring Fair Value Measurements: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Money market mutual funds ​ $ 16,188 ​ $ — ​ $ — ​ $ 16,188 Total ​ $ 16,188 ​ $ — ​ $ — ​ $ 16,188

Nature of Business and Operat_2

Nature of Business and Operations (Details) - IPO $ / shares in Units, $ in Millions	Aug. 02, 2016USD ($)$ / sharesshares
Subsidiary, Sale of Stock
Number of shares of common stock sold | shares	4,120,000
IPO price per share (in dollars per share) | $ / shares	$ 10
Proceeds from IPO	$ 35.4
Expense Relating To Initial Public Offering	$ 2.9

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details)	9 Months Ended
	Sep. 30, 2021segment
Summary of Significant Accounting Policies
Number of operating segment	1
Number of reportable segment	1

Acquisitions (Details)

Acquisitions (Details) $ in Thousands	Sep. 08, 2021USD ($)payment	Sep. 30, 2021USD ($)	Dec. 31, 2020USD ($)
Acquisitions
Earn-out liability fair value		$ 20,000
Property, plant and equipment		$ 6,458	$ 6,957
Reimbursement, general and administrative
Acquisitions
Transaction costs	$ 800
AffloVest APA
Acquisitions
Purchase price	80,000
Escrow account	500
Working capital adjustments	$ 200
Number of earnout payments | payment	2
Threshold earnout payments	$ 10,000
Earn-out liability fair value	6,400
AffloVest APA | Earn-out period exceed Base Revenues from October 1, 2021 to September 30, 2022
Acquisitions
Threshold earnout payments	$ 10,000
Business revenue to exceed base revenue, Multiplier	1.5
AffloVest APA | Earn-out period exceed Base Revenues from October 1, 2022 to September 30, 2023
Acquisitions
Threshold earnout payments	$ 10,000
Business revenue to exceed base revenue, Multiplier	1.5
AffloVest APA | Maximum
Acquisitions
Total consideration transferred	$ 100,000
Property, plant and equipment	$ 100

Acquisitions - Purchase Price A

Acquisitions - Purchase Price Allocation (Details) - USD ($) $ in Thousands	Sep. 08, 2021	Sep. 30, 2021	Dec. 31, 2020
Purchase price allocation
Inventories		$ 23,830	$ 18,563
Property, plant and equipment		6,458	6,957
Intangible assets	$ 53,500	54,970	1,680
Goodwill		31,063
Property and equipment, net		6,458	$ 6,957
Amortization period for tax purposes	15 years
AffloVest APA
Purchase price allocation
Inventories	$ 1,600
Intangible assets	53,500
Goodwill	31,100	$ 31,100
Purchase price	86,200
AffloVest APA | Maximum
Purchase price allocation
Property, plant and equipment	100
Property and equipment, net	$ 100

Acquisitions - Allocation of Pu

Acquisitions - Allocation of Purchase Price (Details) - USD ($) $ in Thousands	Sep. 08, 2021	Sep. 30, 2021	Dec. 31, 2020
Acquisitions
Finite lived intangible assets, Allocated Fair Value		$ 44,840	$ 1,114
Indefinite lived intangible assets excluding goodwill, Allocated fair value		55,917	2,229
Total intangible assets (Net)	$ 53,500	54,970	$ 1,680
Weighted average amortization period	12 years 3 months 18 days
AffloVest APA
Acquisitions
Total intangible assets (Net)	$ 53,500
Customer relationships
Acquisitions
Finite lived intangible assets, Allocated Fair Value	$ 31,000	30,854
Estimated Useful Life	13 years
Developed technology
Acquisitions
Finite lived intangible assets, Allocated Fair Value	$ 13,000	$ 12,928
Estimated Useful Life	11 years
Tradenames
Acquisitions
Indefinite lived intangible assets excluding goodwill, Allocated fair value	$ 9,500

Acquisitions - Condensed Consol

Acquisitions - Condensed Consolidated Statements of Operations Reflect AffloVest Operations (Details) - AffloVest APA - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Asset Acquisition [Line Items]
Total revenue	$ 56,249	$ 53,068	$ 157,686	$ 139,130
Net income (loss)	$ 628	$ (309)	$ 1,369	$ 1,770

Marketable Securities (Details)

Marketable Securities (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)item	Dec. 31, 2020USD ($)item
Marketable Securities
Marketable securities	$ 0	$ 0
Net pre-tax unrealized gains for marketable securities	0
Marketable securities sold	$ 0
Number of marketable securities in an unrealized loss position | item	0	0

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Inventories
Finished goods	$ 9,607	$ 7,129
Component parts and work-in-process	14,223	11,434
Total inventories	$ 23,830	$ 18,563

Goodwill And Intangible Asset_2

Goodwill And Intangible Assets (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Sep. 08, 2021
Patents and Intangibles
Goodwill	$ 31,063		$ 31,063
Definite-lived intangible assets:
Gross Carrying Amount	45,787		45,787		$ 1,663
Accumulated Amortization	947		947		549
Total	44,840		44,840		1,114
Unamortized intangible assets:
Total intangible assets (Gross)	55,917		55,917		2,229
Total intangible assets (Net)	54,970		54,970		1,680	$ 53,500
Amortization expense	300	$ 100	400	$ 300
Future Amortization
2021 (October 1 - December 31)	953		953
2022	3,811		3,811
2023	3,781		3,781
2024	3,759		3,759
2025	3,669		3,669
Thereafter	28,867		28,867
Total	44,840		44,840		1,114
Tradenames
Unamortized intangible assets:
Gross Carrying Amount, Indefinite	9,500		9,500
Patents
Unamortized intangible assets:
Gross Carrying Amount, Indefinite	630		$ 630		$ 566
Patents
Definite-lived intangible assets:
Weighted Average Amortization Period			12 years		11 years
Gross Carrying Amount	537		$ 537		$ 413
Accumulated Amortization	97		97		65
Total	440		440		348
Future Amortization
Total	440		$ 440		$ 348
Defensive intangible assets
Definite-lived intangible assets:
Weighted Average Amortization Period			3 years		4 years
Gross Carrying Amount	1,125		$ 1,125		$ 1,125
Accumulated Amortization	550		550		421
Total	575		575		704
Future Amortization
Total	575		$ 575		$ 704
Customer accounts
Definite-lived intangible assets:
Weighted Average Amortization Period			2 years		2 years
Gross Carrying Amount	125		$ 125		$ 125
Accumulated Amortization	82		82		63
Total	43		43		62
Future Amortization
Total	43		$ 43		$ 62
Customer relationships
Definite-lived intangible assets:
Weighted Average Amortization Period			13 years
Gross Carrying Amount	31,000		$ 31,000
Accumulated Amortization	146		146
Total	30,854		30,854			31,000
Future Amortization
Total	30,854		$ 30,854			31,000
Developed technology
Definite-lived intangible assets:
Weighted Average Amortization Period			11 years
Gross Carrying Amount	13,000		$ 13,000
Accumulated Amortization	72		72
Total	12,928		12,928			13,000
Future Amortization
Total	12,928		12,928			13,000
AffloVest APA
Patents and Intangibles
Goodwill	$ 31,100		$ 31,100			31,100
Unamortized intangible assets:
Total intangible assets (Net)						$ 53,500

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020
Accrued Expenses
Warranty	$ 1,779	$ 1,606	$ 1,443
In-transit inventory	985	882
Legal and consulting	1,341	634
Travel	552	545
Clinical studies	109	193
Sales and use tax	135	67
Other	449	496
Total	$ 5,350	$ 4,423

Warranty Reserves (Details)

Warranty Reserves (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Movement in Standard Product Warranty Accrual [Roll Forward]
Beginning balance	$ 5,117	$ 4,208	$ 4,841	$ 3,759
Warranty provision	624	820	2,080	2,097
Processed warranty claims	(604)	(514)	(1,784)	(1,342)
Ending balance	5,137	4,514	5,137	4,514
Accrued warranty reserve, current	1,779	1,443	1,779	1,443	$ 1,606
Accrued warranty reserve, non-current	3,358	3,071	3,358	3,071	$ 3,235
Total accrued warranty reserve	$ 5,137	$ 4,514	$ 5,137	$ 4,514

Credit Agreement (Details)

Credit Agreement (Details) - USD ($)	Sep. 08, 2021	Sep. 30, 2021
Credit Agreement
Credit facility outstanding amount	$ 25,000,000	$ 24,844,000
Line of credit, threshold contingent increase in borrowing capacity	25,000,000
Credit agreement, total aggregate principal amount	80,000,000
Revolving credit facility
Credit Agreement
Line of credit	25,000,000
Revolving credit facility | Federal Funds
Credit Agreement
Basis spread (as a percent)		0.50%
Revolving credit facility | Base Rate
Credit Agreement
Basis spread (as a percent)		1.00%
Revolving credit facility | LIBOR
Credit Agreement
Basis spread (as a percent)		2.80%
Revolving credit facility | Maximum
Credit Agreement
Unused line fee (as a percent)		0.375%
Revolving credit facility | Maximum | Base Rate
Credit Agreement
Basis spread (as a percent)		2.25%
Revolving credit facility | Maximum | LIBOR
Credit Agreement
Basis spread (as a percent)		3.25%
Revolving credit facility | Minimum
Credit Agreement
Unused line fee (as a percent)		0.30%
Revolving credit facility | Minimum | Base Rate
Credit Agreement
Basis spread (as a percent)		0.75%
Revolving credit facility | Minimum | LIBOR
Credit Agreement
Basis spread (as a percent)		1.75%
Term Loan
Credit Agreement
Debt instrument face amount	30,000,000
Long-term debt	$ 30,000,000	$ 30,000,000
Debt instrument periodic payment		$ 750,000
Debt instrument frequency of periodic payment		quarterly

Credit Agreement - Maturities o

Credit Agreement - Maturities of Debt (Details) - Term Loan - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 08, 2021
Maturities of notes payable
2022	$ 3,000
2023	3,000
2024	24,000
Total	$ 30,000	$ 30,000

Commitments and Contingencies -

Commitments and Contingencies - Lease Obligations (Details)	9 Months Ended
	Sep. 30, 2021item	Dec. 31, 2019ft²	Dec. 31, 2018ft²	Oct. 31, 2018ft²
Minimum
Commitments and Contingencies
Remaining lease terms	12 months
Building | Minimum
Commitments and Contingencies
Remaining lease terms	1 year
Building | Maximum
Commitments and Contingencies
Remaining lease terms	9 years
Vehicles
Commitments and Contingencies
Remaining lease terms	367 days
Number of vehicles with agreements within the initial, noncancelable lease term | item	45
Equipment
Commitments and Contingencies
Option to renew	true
Equipment | Minimum
Commitments and Contingencies
Remaining lease terms	1 year
Equipment | Maximum
Commitments and Contingencies
Remaining lease terms	4 years
Initial lease
Commitments and Contingencies
Area of office space				80,000
Second lease
Commitments and Contingencies
Area of office space			29,000
Additional office space added to the lease		4,000
Third lease
Commitments and Contingencies
Additional office space added to the lease		37,000

Commitments and Contingencies_2

Commitments and Contingencies - Lease related assets and liabilities (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Lease-related assets and liabilities
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]	Right of use operating lease assets		Right of use operating lease assets
Right of use operating lease assets	$ 23,919		$ 20,132
Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]	Operating lease liabilities, Current		Operating lease liabilities, Current
Operating lease liabilities, Current	$ 2,412		$ 2,006
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Operating lease liabilities, non-current		Operating lease liabilities, non-current
Operating lease liabilities, non-current	$ 23,357		$ 19,388
Present value of future minimum lease payments	$ 25,769		$ 21,394
Weighted average remaining lease term	8 years 10 months 24 days		9 years 4 months 24 days
Weighted average discount rate	4.20%		4.40%
Cash paid for operating lease liabilities	$ 2,411	$ 1,849
Non-cash right of use assets obtained in exchange for new operating lease obligations	$ 6,146	$ 6,664

Commitments and Contingencies_3

Commitments and Contingencies - Undiscounted cash flows (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Undiscounted cash flows
2021 (October 1 - December 31)	$ 908
2022	3,345
2023	3,274
2024	3,260
2025	3,359
Thereafter	16,653
Total minimum lease payments	30,799
Less: Amount of lease payments representing interest	(5,030)
Present value of future minimum lease payments	25,769	$ 21,394
Less: Current obligations under operating lease liabilities	(2,412)	(2,006)
Non-current obligations under operating lease liabilities	$ 23,357	$ 19,388

Commitments and Contingencies_4

Commitments and Contingencies - Lease commitments and operating lease cost (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Commitments and Contingencies
Additional lease commitments	$ 0.8		$ 0.8
Operating lease cost	$ 0.9	$ 0.8	$ 2.6	$ 2.1

Commitments and Contingencies_5

Commitments and Contingencies - Major Vendors (Details) - item	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Vendor One
Commitments and Contingencies
Number of vendors	1		1
Vendor Two
Commitments and Contingencies
Number of vendors	2	2	2	2
Purchases | Vendor | Vendor One
Commitments and Contingencies
Total purchases (in percentage)			24.00%
Purchases | Vendor | Vendor Two
Commitments and Contingencies
Total purchases (in percentage)	36.00%	31.00%		33.00%

Commitments and Contingencies_6

Commitments and Contingencies - Purchase Commitments (Details) $ in Millions	Sep. 30, 2021USD ($)
Purchase commitments
Purchase orders issued	$ 28.4

Commitments and Contingencies_7

Commitments and Contingencies - Retirement Plan (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
401(k)
Retirement Plan
Discretionary contributions	$ 0.3	$ 0.1	$ 0.9	$ 0.2

Stockholders' Equity - Stock-Ba

Stockholders' Equity - Stock-Based Compensation General Information (Details)	Sep. 30, 2021shares
2016 Plan
Stockholders' Equity
Number of shares authorized	4,800,000

Stockholders' Equity - Stock-_2

Stockholders' Equity - Stock-Based Compensation Expense (Details) - USD ($) $ in Thousands	Jan. 01, 2021	Jan. 01, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Stock-based compensation
Compensation expense			$ 2,588	$ 3,164	$ 7,703	$ 8,288
Cost of revenue.
Stock-based compensation
Compensation expense			171	171	455	358
Sales and marketing
Stock-based compensation
Compensation expense			1,081	1,436	2,979	3,915
Research and development
Stock-based compensation
Compensation expense			68	87	224	269
Reimbursement, general and administrative
Stock-based compensation
Compensation expense			$ 1,268	1,470	$ 4,045	3,746
2016 Plan
Stock-based compensation
Shares available for future issuance			6,366,806		6,366,806
Automatic annual increase to the number of shares reserved and available for issuance as a percentage of outstanding common stock (as a percent)			5.00%		5.00%
Automatic annual increase to the number of shares reserved and available for issuance			2,500,000		2,500,000
Increase in number of shares reserved and available for issuance	972,591	952,697
Common stock options
Stock-based compensation
Compensation expense			$ 1,000	$ 1,100	$ 3,300	$ 3,000
Unrecognized stock-based compensation
Unrecognized stock-based compensation expense, period for recognition					1 year 10 months 24 days

Stockholders' Equity - Stock Op

Stockholders' Equity - Stock Options and Restricted Stock (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Stock-based compensation, general disclosures.
Stock-based compensation expense	$ 2,588	$ 3,164	$ 7,703	$ 8,288
Common stock options
Stock-based compensation, general disclosures.
Stock-based compensation expense	1,000	$ 1,100	3,300	$ 3,000
Total unrecognized pre-tax compensation expense related to nonvested stock option awards	$ 6,400		$ 6,400
Weighted-average period over which unrecognized compensation cost is expected to be recognized			1 year 10 months 24 days
Options Outstanding
Outstanding at beginning of period			1,039,709
Granted			174,755
Exercised			(138,586)
Forfeited			(68,797)
Cancelled/Expired			(30,005)
Outstanding at end of period	977,076		977,076		1,039,709
Weighted Average Exercise Price Per Share
Outstanding at beginning of period			$ 36.43
Granted			50.88
Exercised			25.85
Forfeited			48.64
Cancelled/Expired			61.13
Outstanding at end of period	$ 38.90		$ 38.90		$ 36.43
Other information
Options exercisable number of shares exercisable	508,184	461,138	508,184	461,138
Options exercisable, weighted-average exercise price	$ 30.45	$ 23.35	$ 30.45	$ 23.35
Weighted average remaining contractual life (in years)			5 years 2 months 12 days		5 years 7 months 6 days
Options exercisable, weighted-average remaining contractual life			4 years 4 months 24 days
Aggregate Intrinsic Value, Options outstanding	$ 10,208		$ 10,208		$ 13,381
Aggregate Intrinsic Value, Exercised			3,863
Aggregate Intrinsic Value, Options exercisable	$ 9,229		$ 9,229
Common stock options | Minimum
Stock-based compensation, general disclosures.
Vesting period (in years)			3 years
Term (in years)			7 years
Common stock options | Maximum
Stock-based compensation, general disclosures.
Vesting period (in years)			4 years
Term (in years)			10 years
Common stock options | Chief Executive Officer [Member]
Stock-based compensation, general disclosures.
Share-based payment award, term			7 years
Vesting period (in years)			3 years
Number of consecutive trading days			20 days
Common stock options | Chief Executive Officer [Member] | Minimum
Stock-based compensation, general disclosures.
Stock price	$ 40.15		$ 40.15
Time-Based Restricted Stock Units
Stock-based compensation, general disclosures.
Stock-based compensation expense			$ 3,700	$ 4,000
Time-Based Restricted Stock Units | Non-employee Directors
Units Outstanding
Granted (in shares)			0
Number of granted and vested restricted stock units	6,469		6,469
2018 and 2021 PSUs
Stock-based compensation, general disclosures.
Stock-based compensation expense			$ 500
2016 Plan | Time-Based Restricted Stock Units
Stock-based compensation, general disclosures.
Stock-based compensation expense	$ 1,200	$ 1,400
Total unrecognized pre-tax compensation expense related to awards	$ 6,600		$ 6,600
Weighted-average period over which unrecognized compensation cost is expected to be recognized			1 month 27 days
Units Outstanding
Restricted stock unit awards outstanding at the beginning of the period (in shares)			211,469
Granted (in shares)			91,001
Vested (in shares)			94,517
Cancelled (in shares)			(24,161)
Restricted stock unit awards outstanding at the end of the period (in shares)	183,792		183,792		211,469
Deferred and unissued (in shares)	6,469		6,469
Weighted Average Grant Date Fair Value Per Unit
Restricted stock unit awards outstanding at the beginning of the period (in dollars per share)			$ 48.29
Granted (in dollars per share)			51.56
Vested (in dollars per share)			47.99
Cancelled (in dollars per share)			51.29
Restricted stock unit awards outstanding at the end of the period (in dollars per share)	$ 49.66		49.66		$ 48.29
Deferred and unissued (in dollars per share)	$ 38.94		$ 38.94
Aggregate Intrinsic Value
Restricted stock unit awards, Average Intrinsic Value	$ 8,170		$ 8,170		$ 9,503
Restricted stock unit awards deferred and unissued, Average Intrinsic Value	288		$ 288
2016 Plan | Time-Based Restricted Stock Units | Minimum
Stock-based compensation, general disclosures.
Vesting period (in years)			1 year
2016 Plan | Time-Based Restricted Stock Units | Maximum
Stock-based compensation, general disclosures.
Vesting period (in years)			3 years
2016 Plan | Performance-based stock-settled restricted stock units
Stock-based compensation, general disclosures.
Estimated payout			$ 500
Stock-based compensation expense	200	$ 400		$ 500
Total unrecognized pre-tax compensation expense related to awards	$ 1,500		$ 1,500
Weighted-average period over which unrecognized compensation cost is expected to be recognized			2 years 4 months 24 days
Units Outstanding
Restricted stock unit awards outstanding at the beginning of the period (in shares)			79,303
Granted (in shares)			39,419
Vested (in shares)			34,159
Cancelled (in shares)			(23,936)
Restricted stock unit awards outstanding at the end of the period (in shares)	60,627		60,627		79,303
Weighted Average Grant Date Fair Value Per Unit
Restricted stock unit awards outstanding at the beginning of the period (in dollars per share)			$ 47.83
Granted (in dollars per share)			51.82
Vested (in dollars per share)			33.98
Cancelled (in dollars per share)			65.43
Restricted stock unit awards outstanding at the end of the period (in dollars per share)	$ 51.28		$ 51.28		$ 47.83
Aggregate Intrinsic Value
Restricted stock unit awards, Average Intrinsic Value	$ 2,695		$ 2,695		$ 3,564
2016 Plan | Performance-based stock-settled restricted stock units | Minimum
Units Outstanding
Percentage to earn or vest the performance-based stock-settled restricted stock units			50.00%
2016 Plan | Performance-based stock-settled restricted stock units | Maximum
Stock-based compensation, general disclosures.
Stock-based compensation expense			$ 100
Units Outstanding
Percentage to earn or vest the performance-based stock-settled restricted stock units			150.00%
2016 Plan | Tranche one | Performance-based stock-settled restricted stock units
Stock-based compensation, general disclosures.
Compensation arrangement			33.33%
2016 Plan | Tranche two | Performance-based stock-settled restricted stock units
Stock-based compensation, general disclosures.
Compensation arrangement			66.67%

Stockholders' Equity - Employee

Stockholders' Equity - Employee Stock Purchase Plan (Details) - USD ($) $ in Thousands	Jan. 01, 2021	Jan. 01, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Apr. 27, 2017
Stockholders' Equity
Stock-based compensation expense			$ 2,588	$ 3,164	$ 7,703	$ 8,288
Employee Stock Purchase Plan
Stockholders' Equity
Purchase price of common stock under plan (as a percent)					85.00%
Offering period (in months)					6 months
Shares reserved			1,740,328		1,740,328		1,600,000
Incremental share increase (in shares)					500,000
Incremental share increase (as a percent)					1.00%
Increase in number of shares reserved and available for issuance	194,518	190,539
Stock-based compensation expense			$ 200	$ 300	$ 600	$ 800

Revenue (Details)

Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenue
Revenue	$ 52,497	$ 49,092	$ 146,329	$ 127,887
Percentage of total revenue (in percent)	100.00%	100.00%	100.00%	100.00%
Revenue from sale type lease
Sales-type lease revenue	$ 8,037	$ 6,519	$ 22,114	$ 18,173
Cost of sales-type lease revenue	2,433	2,562	6,501	6,062
Gross profit	5,604	3,957	15,613	12,111
Private insurers and other payers
Revenue
Revenue	36,034	34,554	99,665	90,459
Veterans Administration
Revenue
Revenue	6,737	6,788	19,905	18,168
Medicare
Revenue
Revenue	8,865	7,750	25,898	19,260
Durable medical equipment distributors
Revenue
Revenue	861		861
Flexitouch system
Revenue
Revenue	$ 44,014	$ 42,908	$ 126,544	$ 112,621
Percentage of total revenue (in percent)	84.00%	87.00%	86.00%	88.00%
Entre system
Revenue
Revenue	$ 7,622	$ 6,184	$ 18,924	$ 15,266
Percentage of total revenue (in percent)	14.00%	13.00%	13.00%	12.00%
AffloVest
Revenue
Revenue	$ 861		$ 861
Percentage of total revenue (in percent)	2.00%		1.00%

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Taxes
Net effective rate	126.00%	(55.00%)	(24.00%)	17.00%
Income tax expense (benefit)	$ 1,868	$ (751)	$ (1,365)	$ 2,294
Tax contingencies			$ 500
Change in deductibility of business meals			100.00%	50.00%

Net (Loss) Income Per Share - B

Net (Loss) Income Per Share - Basic and Diluted Net (Loss) Income Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Net (Loss) Income Per Share
Net (loss) income	$ (3,355)	$ 2,424	$ (4,316)	$ (12,733)
Weighted-average shares outstanding	19,790,838	19,415,640	19,676,749	19,309,344
Dilutive effect of stock-based awards		331,725
Weighted-average shares used to compute diluted net (loss) income per share	19,790,838	19,747,365	19,676,749	19,309,344
Net (loss) income per share - Basic	$ (0.17)	$ 0.12	$ (0.22)	$ (0.66)
Net (loss) income per share - Diluted	$ (0.17)	$ 0.12	$ (0.22)	$ (0.66)

Net (Loss) Income Per Share - A

Net (Loss) Income Per Share - Antidilutive Securities Excluded From Computation of Earnings Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Net Income (Loss) Per Share
Antidilutive securities excluded from computation of earnings per share	1,266,289	797,765	1,261,895	1,367,964
Common stock options
Net Income (Loss) Per Share
Antidilutive securities excluded from computation of earnings per share	977,076	594,117	977,076	982,182
Performance stock units
Net Income (Loss) Per Share
Antidilutive securities excluded from computation of earnings per share	60,627	38,666	60,627	113,646
Restricted Stock Units
Net Income (Loss) Per Share
Antidilutive securities excluded from computation of earnings per share	190,261	104,786	190,261	223,776
Employee stock purchase plan
Net Income (Loss) Per Share
Antidilutive securities excluded from computation of earnings per share	38,325	60,196	33,931	48,360

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Sep. 08, 2021	Dec. 31, 2020	Jun. 30, 2020
Fair Value Measurements
Amount of transfers of marketable securities within the three level hierarchy	$ 0
Intangible assets	54,970	$ 53,500	$ 1,680
Earn-out liability fair value	$ 20,000
Recurring
Fair Value Measurements
Available for sale debt securities			16,188
Recurring | Money market mutual funds
Fair Value Measurements
Money market mutual funds			16,188
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value Measurements
Available for sale debt securities			16,188
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Money market mutual funds
Fair Value Measurements
Money market mutual funds			$ 16,188
Non-recurring | Significant Unobservable Inputs (Level 3) | Airwear Product
Fair Value Measurements
Intangible assets				$ 0